<?xml version="1.0" encoding="UTF-8" standalone="no"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD Journal Publishing DTD v2.3 20070202//EN" "journalpublishing.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article">
<front>
<journal-meta>
<journal-id journal-id-type="publisher-id">Front. Immunol.</journal-id>
<journal-title>Frontiers in Immunology</journal-title>
<abbrev-journal-title abbrev-type="pubmed">Front. Immunol.</abbrev-journal-title>
<issn pub-type="epub">1664-3224</issn>
<publisher>
<publisher-name>Frontiers Media S.A.</publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="doi">10.3389/fimmu.2013.00342</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Immunology</subject>
<subj-group>
<subject>Original Research</subject>
</subj-group>
</subj-group>
</article-categories>
<title-group>
<article-title>Association Analysis of <italic>IL10, TNF</italic>-&#x003B1;, and <italic>IL23R</italic>-<italic>IL12RB2</italic> SNPs with Beh&#x000E7;et&#x02019;s Disease Risk in Western Algeria</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name><surname>Khaib Dit Naib</surname> <given-names>Ouahiba</given-names></name>
<xref ref-type="aff" rid="aff1"><sup>1</sup></xref>
<uri xlink:href="http://frontiersin.org/people/u/113461"/>
</contrib>
<contrib contrib-type="author" corresp="yes">
<name><surname>Aribi</surname> <given-names>Mourad</given-names></name>
<xref ref-type="aff" rid="aff1"><sup>1</sup></xref>
<xref ref-type="aff" rid="aff2"><sup>2</sup></xref>
<xref ref-type="corresp" rid="cor1">&#x0002A;</xref>
<uri xlink:href="http://frontiersin.org/people/u/83480"/>
</contrib>
<contrib contrib-type="author">
<name><surname>Idder</surname> <given-names>Aicha</given-names></name>
<xref ref-type="aff" rid="aff3"><sup>3</sup></xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Chiali</surname> <given-names>Amel</given-names></name>
<xref ref-type="aff" rid="aff4"><sup>4</sup></xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Sairi</surname> <given-names>Hakim</given-names></name>
<xref ref-type="aff" rid="aff4"><sup>4</sup></xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Touitou</surname> <given-names>Isabelle</given-names></name>
<xref ref-type="aff" rid="aff5"><sup>5</sup></xref>
<xref ref-type="aff" rid="aff6"><sup>6</sup></xref>
<xref ref-type="aff" rid="aff7"><sup>7</sup></xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Lefranc</surname> <given-names>G&#x000E9;rard</given-names></name>
<xref ref-type="aff" rid="aff8"><sup>8</sup></xref>
<uri xlink:href="http://frontiersin.org/people/u/116866"/>
</contrib>
<contrib contrib-type="author">
<name><surname>Barat-Houari</surname> <given-names>Mouna</given-names></name>
<xref ref-type="aff" rid="aff5"><sup>5</sup></xref>
<uri xlink:href="http://frontiersin.org/people/u/117074"/>
</contrib>
</contrib-group>
<aff id="aff1"><sup>1</sup><institution>Laboratory of Applied Molecular Biology and Immunology. Department of Biology, Abou-Bekr Belka&#x000EF;d University</institution>, <addr-line>Tlemcen</addr-line>, <country>Algeria</country></aff>
<aff id="aff2"><sup>2</sup><institution>Departments of Pharmacy and Oral Medicine, Abou-Bekr Belka&#x000EF;d University</institution>, <addr-line>Tlemcen</addr-line>, <country>Algeria</country></aff>
<aff id="aff3"><sup>3</sup><institution>Etablissement Hospitalier Sp&#x000E9;cialis&#x000E9; en Ophtalmologie, Clinique Hamou Boutlelis</institution>, <addr-line>Oran</addr-line>, <country>Algeria</country></aff>
<aff id="aff4"><sup>4</sup><institution>Service de Dermatologie, Centre Hospitalo-Universitaire d&#x02019;Oran</institution>, <addr-line>Oran</addr-line>, <country>Algeria</country></aff>
<aff id="aff5"><sup>5</sup><institution>Unit&#x000E9; M&#x000E9;dicale des Maladies Auto-inflammatoires, D&#x000E9;partement de G&#x000E9;n&#x000E9;tique, CHRU</institution>, <addr-line>Montpellier</addr-line>, <country>France</country></aff>
<aff id="aff6"><sup>6</sup><institution>Universit&#x000E9; Montpellier 1</institution>, <addr-line>Montpellier</addr-line>, <country>France</country></aff>
<aff id="aff7"><sup>7</sup><institution>G&#x000E9;n&#x000E9;tique des Maladies Auto-inflammatoires et des Ost&#x000E9;o-arthropathies chroniques, INSERM U844</institution>, <addr-line>Montpellier</addr-line>, <country>France</country></aff>
<aff id="aff8"><sup>8</sup><institution>Laboratoire d&#x02019;Immunog&#x000E9;n&#x000E9;tique Mol&#x000E9;culaire, Institut de G&#x000E9;n&#x000E9;tique Humaine, CNRS UPR 1142, et Universit&#x000E9; Montpellier 2</institution>, <addr-line>Montpellier</addr-line>, <country>France</country></aff>
<author-notes>
<fn fn-type="edited-by"><p>Edited by: Giuseppe Alvise Ramirez, Universit&#x000E0; Vita-Salute San Raffaele, Italy</p></fn>
<fn fn-type="edited-by"><p>Reviewed by: Fulvio D&#x02019;Acquisto, Queen Mary University of London, UK; Angelo A. Manfredi, Universit&#x000E0; Vita-Salute San Raffaele, Italy</p></fn>
<corresp content-type="corresp" id="cor1">&#x0002A;Correspondence: Mourad Aribi, Laboratory of Applied Molecular Biology and Immunology, Abou-Bekr Belka&#x000EF;d University of Tlemcen, Rocade &#x00023; 2, Tlemcen, TLM 13000, Algeria e-mail: <email>m_aribi&#x00040;mail.univ-tlemcen.dz</email>; <email>m_aribi&#x00040;yahoo.fr</email></corresp>
<fn fn-type="other" id="fn001"><p>This article was submitted to Inflammation, a section of the journal Frontiers in Immunology.</p></fn>
</author-notes>
<pub-date pub-type="epub">
<day>21</day>
<month>10</month>
<year>2013</year>
</pub-date>
<pub-date pub-type="collection">
<year>2013</year>
</pub-date><volume>4</volume>
<elocation-id>342</elocation-id>
<history>
<date date-type="received">
<day>27</day>
<month>07</month>
<year>2013</year>
</date>
<date date-type="accepted">
<day>06</day>
<month>10</month>
<year>2013</year>
</date>
</history>
<permissions>
<copyright-statement>Copyright &#x000A9; 2013 Khaib Dit Naib, Aribi, Idder, Chiali, Sairi, Touitou, Lefranc and Barat-Houari.</copyright-statement>
<copyright-year>2013</copyright-year>
<license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by/3.0/"><p>This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.</p></license>
</permissions>
<abstract>
<p><bold>Objective:</bold> We have conducted the first study of the association of interleukin (IL)-10, tumor necrosis factor alpha (<italic>TNF</italic>-&#x003B1;), and <italic>IL23R</italic>-<italic>IL12RB2</italic> region single nucleotide polymorphisms (SNPs) with Beh&#x000E7;et&#x02019;s disease (BD) in Western Algeria.</p>
<p><bold>Methods:</bold> A total of 51 BD patients and 96 unrelated controls from West region of Algeria were genotyped by direct sequencing for 11 SNPs including 2 SNPs from the <italic>IL10</italic> promoter [c.-819T&#x02009;&#x0003E;&#x02009;C (rs1800871), c.-592A&#x02009;&#x0003E;&#x02009;C (rs1800872)], 6 SNPs from the <italic>TNF</italic>-&#x003B1; promoter [c.-1211T&#x02009;&#x0003E;&#x02009;C (rs1799964), c.-1043C&#x02009;&#x0003E;&#x02009;A (rs1800630), c.-1037C&#x02009;&#x0003E;&#x02009;T (rs1799724), c.-556G&#x02009;&#x0003E;&#x02009;A (rs1800750), c.-488G&#x02009;&#x0003E;&#x02009;A (rs1800629), and c.-418G&#x02009;&#x0003E;&#x02009;A (rs361525)], and 3 SNPs from the <italic>IL23R</italic>-<italic>IL12RB2</italic> region [g.67747415A&#x02009;&#x0003E;&#x02009;C (rs12119179), g.67740092G&#x02009;&#x0003E;&#x02009;A (rs11209032), and g.67760140T&#x02009;&#x0003E;&#x02009;C (rs924080)].</p>
<p><bold>Results:</bold> The minor alleles c.-819T and c.-592A were significantly associated with BD [odds ratio (OR)&#x02009;&#x0003D;&#x02009;2.18; 95% confidence interval (CI) 1.28&#x02013;3.73, <italic>p</italic>&#x02009;&#x0003D;&#x02009;0.003]; whereas, there was weaker association between <italic>TNF</italic>-&#x003B1; promoter SNPs or <italic>IL23R</italic>-<italic>IL12RB2</italic> region and disease risk.</p>
<p><bold>Conclusion:</bold> Unlike the <italic>TNF</italic>-&#x003B1; and the <italic>IL23R</italic>-<italic>IL12RB2</italic> region SNPs, the two <italic>IL10</italic> SNPs were strongly associated with BD. The -819T, and -592A alleles and the -819TT, -819CT, and -592AA and -592CA genotypes seem to be highly involved in the risk of developing of BD in the population of Western Algeria.</p>
</abstract>
<kwd-group>
<kwd>Beh&#x000E7;et&#x02019;s disease</kwd>
<kwd>genetic association</kwd>
<kwd><italic>IL10</italic></kwd>
<kwd><italic>TNF</italic>-&#x003B1;</kwd>
<kwd><italic>IL23R</italic>-<italic>IL12RB2</italic></kwd>
<kwd>single nucleotide polymorphism</kwd>
<kwd>Western Algeria</kwd>
</kwd-group>
<counts>
<fig-count count="2"/>
<table-count count="7"/>
<equation-count count="0"/>
<ref-count count="76"/>
<page-count count="10"/>
<word-count count="7214"/>
</counts>
</article-meta>
</front>
<body>
<sec id="S1" sec-type="introduction">
<title>Introduction</title>
<p>Beh&#x000E7;et&#x02019;s disease (BD) is a systemic inflammatory multifactorial disease (<xref ref-type="bibr" rid="B1">1</xref>). It is characterized by recurrent episodes of oral and genital ulceration, skin, and ocular lesions (<xref ref-type="bibr" rid="B2">2</xref>). The disease is now recognized as a systemic vasculitis, given that it can affect other tissues and organs including blood vessels, the digestive tract, and nervous system (<xref ref-type="bibr" rid="B3">3</xref>, <xref ref-type="bibr" rid="B4">4</xref>).</p>
<p>The etiology of BD is not fully elucidated. There is a hypothesis that a pathogenic autoimmune process of BD is triggered by an infectious or environmental agent, in individuals genetically predisposed (<xref ref-type="bibr" rid="B5">5</xref>). The most strongly genetic factor associated with the disease is HLA B51 (<xref ref-type="bibr" rid="B5">5</xref>, <xref ref-type="bibr" rid="B6">6</xref>). This association was initially described in 1973 (<xref ref-type="bibr" rid="B7">7</xref>) and subsequently confirmed in different ethnic groups (<xref ref-type="bibr" rid="B6">6</xref>, <xref ref-type="bibr" rid="B8">8</xref>, <xref ref-type="bibr" rid="B9">9</xref>).</p>
<p>However, the association between BD and HLA B51 represents only 20% in the siblings of patients with the disease (<xref ref-type="bibr" rid="B10">10</xref>), and 50% of cases with BD are negative for this allele (<xref ref-type="bibr" rid="B8">8</xref>, <xref ref-type="bibr" rid="B9">9</xref>). These observations suggest the existence of other risk factors outside the HLA region. In fact, several recent genome-wide association studies have identified additional and new genomic regions that predispose to the disease (<xref ref-type="bibr" rid="B11">11</xref>&#x02013;<xref ref-type="bibr" rid="B14">14</xref>).</p>
<p>The BD causes inflammation and chronic immune activation within small blood vessels (<xref ref-type="bibr" rid="B15">15</xref>&#x02013;<xref ref-type="bibr" rid="B17">17</xref>). The site of inflammation is usually characterized by infiltration of immune cells as well as by highly elevated levels of different cytokines (<xref ref-type="bibr" rid="B18">18</xref>). IL-10 is one of the most important cytokines that has been observed at increased level in the serum and active lesions of BD patients (<xref ref-type="bibr" rid="B19">19</xref>&#x02013;<xref ref-type="bibr" rid="B21">21</xref>). TNF-&#x003B1; and soluble TNF-&#x003B1; receptors are also elevated in the sera of patients with BD (<xref ref-type="bibr" rid="B22">22</xref>&#x02013;<xref ref-type="bibr" rid="B24">24</xref>). Both IL-10 and TNF-&#x003B1; cytokines have been shown to play an important role in the immunopathology of autoimmune diseases (<xref ref-type="bibr" rid="B25">25</xref>&#x02013;<xref ref-type="bibr" rid="B28">28</xref>), and an opposite roles in the inflammatory responses (<xref ref-type="bibr" rid="B29">29</xref>, <xref ref-type="bibr" rid="B30">30</xref>). An autoregulatory loop appears to exist in whereby TNF-&#x003B1; induces IL-10 production, which ultimately reduces TNF-&#x003B1; synthesis (<xref ref-type="bibr" rid="B31">31</xref>, <xref ref-type="bibr" rid="B32">32</xref>). It has been suggested that the increase of IL-10 may down-regulate the expression of NO, prompting the protective role of elevation of IL-10 (<xref ref-type="bibr" rid="B33">33</xref>). Additionally, treatment with anti-TNF-&#x003B1; monoclonal antibodies has resulted in improvement of various manifestations of BD (<xref ref-type="bibr" rid="B34">34</xref>, <xref ref-type="bibr" rid="B35">35</xref>).</p>
<p>IL-10 and TNF-&#x003B1; production may be regulated at the transcriptional level. Thus, several single nucleotide polymorphisms (SNPs) at the promoter of <italic>IL10</italic> and <italic>TNF</italic>-&#x003B1; gene have been shown to be associated with changes in the expression levels of IL-10 and TNF-&#x003B1; production (<xref ref-type="bibr" rid="B36">36</xref>, <xref ref-type="bibr" rid="B37">37</xref>). On the other hand, numerous recent studies have demonstrated an association between BD and several <italic>IL10</italic> (<xref ref-type="bibr" rid="B13">13</xref>, <xref ref-type="bibr" rid="B14">14</xref>, <xref ref-type="bibr" rid="B38">38</xref>, <xref ref-type="bibr" rid="B39">39</xref>) and <italic>TNF</italic>-&#x003B1; (<xref ref-type="bibr" rid="B39">39</xref>&#x02013;<xref ref-type="bibr" rid="B43">43</xref>) SNPs in different ethnic groups. However, to date, there are no analogous or identical investigations in Algeria.</p>
<p>Two others cytokines, IL-23 and IL-12, may play an important role in BD pathogenesis; their levels are elevated in BD patients (<xref ref-type="bibr" rid="B44">44</xref>&#x02013;<xref ref-type="bibr" rid="B46">46</xref>). IL-23 drives and promotes the development of a unique T-helper cell population that produces IL-17, Th17 cells. These IL-23-driven Th17 cells are highly pathogenic and elicit IL-17-dependent inflammation in autoimmune diseases (<xref ref-type="bibr" rid="B47">47</xref>). IL-12, a heterodimeric cytokine, is of crucial relevance to cell-mediated immunity and Th1 differentiation (<xref ref-type="bibr" rid="B48">48</xref>). This cytokine exerts its biological effects <italic>via</italic> binding to a heterodimeric receptor consisting of IL12RB2 and IL-12RB1 subunits.</p>
<p>The effect of IL-23 and IL-12 is mediated through the IL-23 and the IL-12 receptor (IL-23R, IL-12RB1). The genes that encode these receptors are adjacent on chromosome 1p31; a GWAS Studies revealed that <italic>IL23R</italic>-<italic>IL12RB2</italic> region is associated with BD (<xref ref-type="bibr" rid="B13">13</xref>, <xref ref-type="bibr" rid="B14">14</xref>). Nevertheless, its association in the pathogenesis of BD remains to be confirmed in different ethnic groups. In this context, we examined genetic association for 11 SNPs in <italic>IL10, TNF</italic>-&#x003B1;, and <italic>IL23R</italic>-<italic>IL12RB2</italic> candidate genes with BD in Western Algeria.</p>
</sec>
<sec id="S2" sec-type="materials|methods">
<title>Materials and Methods</title>
<sec id="S2-1">
<title>Patients and subjects</title>
<p>Fifty-one (51) unrelated BD patients and age- and sex-matched 96 healthy controls originate from the Western Algeria were recruited for a case-control study at the Oran Ophthalmic Hamou Boutlelis Hospital, the Department of Dermatology of Oran Medical Centre University, and the Oran Blood Transfusion Centre (Algeria). Among the 51 patients, 11 DNA belonging to Algerian origin, were selected from the biobank DNA for Genetics Laboratory of Autoinflammatory Diseases, Arnaud de Villeneuve Hospital, Montpellier (France).</p>
<p>Consent was signed by each participant or participant&#x02019;s parent or legal guardian if entrant is a minor, under the Rules of Ethics and Professional Conduct. Patient characteristics were recorded using a questionnaire. The diagnosis of patients was based especially on the criteria proposed in 1990 (<xref ref-type="bibr" rid="B49">49</xref>). The control group was composed of healthy subjects without a family history of autoinflammatory diseases, and selected from the same population. This work was approved by the Institutional Ethics Board of Tlemcen Abou-Bekr Belka&#x000EF;d University.</p>
</sec>
<sec id="S2-2">
<title>Genotyping</title>
<p>Each DNA was genotyped for 11 SNPs, including two <italic>IL10</italic> promoter SNPs [c.-819T&#x02009;&#x0003E;&#x02009;C (rs1800871), c.-592A&#x02009;&#x0003E;&#x02009;C (rs1800872)], six SNPs from the <italic>TNF</italic>-&#x003B1; promoter [c.-1211T&#x02009;&#x0003E;&#x02009;C (rs1799964), c.-1043C&#x02009;&#x0003E;&#x02009;A (rs1800630), c.-1037C&#x02009;&#x0003E;&#x02009;T (rs1799724), c.-556G&#x02009;&#x0003E;&#x02009;A (rs1800750), c.-488G&#x02009;&#x0003E;&#x02009;A (rs1800629), and c.-418G&#x02009;&#x0003E;&#x02009;A (rs361525)], and three SNPs from the <italic>IL23R</italic>-<italic>IL12RB2</italic> region [g.67747415A&#x02009;&#x0003E;&#x02009;C (rs12119179), g.67740092G&#x02009;&#x0003E;&#x02009;A (rs11209032), and g.67760140T&#x02009;&#x0003E;&#x02009;C (rs924080)].</p>
<p>Genotyping was performed at the Laboratory of Genetics of Autoinflammatory Diseases, Arnaud de Villeneuve Hospital, Montpellier (France). Genomic DNA was isolated from peripheral blood, drawed on EDTA anti-coagulant, using QIAamp DNA Blood Kits (Qiagen, Valencia, CA, USA). The DNA samples were then dosed by spectrophotometry ND-1000 (Nano Drop Technologies, Wilmington, DE, USA) at 260 and 280&#x02009;nm. The DNA concentration and ratio OD260/OD280 were estimated for each sample (<xref ref-type="bibr" rid="B50">50</xref>).</p>
<p>The DNA samples were subsequently amplified in a Applied Biosystems Thermocycler (Applied Biosystems, Foster City, CA, USA) in a 15&#x02009;&#x003BC;L reaction volume containing 50&#x02009;ng DNA, 2X Promega PCR Master Mix, and 25&#x02009;&#x003BC;M of each primer (Table <xref ref-type="table" rid="T1">1</xref>). The PCR programs were as follows: after a denaturation phase of 15&#x02009;min at 95&#x000B0;C, the samples were subjected to 35 amplification cycles followed by a final elongation step of 7&#x02009;min at 72&#x000B0;C. Each cycle comprises 30&#x02009;s denaturation at 95&#x000B0;C, 30&#x02009;s of primer annealing at 60&#x000B0;C, and 1&#x02009;min extension at 72&#x000B0;C.</p>
<table-wrap position="float" id="T1">
<label>Table 1</label>
<caption><p><bold>Primers sequence and length product</bold>.</p></caption>
<table frame="hsides" rules="groups">
<thead>
<tr>
<th align="left">Loci</th>
<th align="left">SNPs</th>
<th align="left">Forward primer</th>
<th align="left">Reverse primer</th>
<th align="center">Product length (bp)</th>
</tr>
</thead>
<tbody>
<tr>
<td align="left"><italic>IL10</italic></td>
<td align="left">rs1800871 rs1800872</td>
<td align="left">TTAGACTCCAGCCACAGAAGC</td>
<td align="left">GGGGGACCCAATTATTTCTC</td>
<td align="center">597</td>
</tr>
<tr>
<td align="left"><italic>TNF-&#x003B1;</italic></td>
<td align="left">rs1799964 rs1800630 rs1799724</td>
<td align="left">GTGTGTCTGGGAGTGAGAACTTC</td>
<td align="left">CTTCTTTCATTCTGACCCGG</td>
<td align="center">570</td>
</tr>
<tr>
<td align="left"/>
<td align="left">rs1800750 rs1800629 rs611525</td>
<td align="left">CTCAGGACTCAACACAGCTTTTC</td>
<td align="left">GAAAGAATCATTCAACCAGCG</td>
<td align="center">438</td>
</tr>
<tr>
<td align="left"><italic>IL23R-IL12RB2</italic> region</td>
<td align="left">rs11209032</td>
<td align="left">GGAGTTAAACCTCTTGCTATCCTG</td>
<td align="left">GATGCACAATGAGTTGATAAGG</td>
<td align="center">164</td>
</tr>
<tr>
<td align="left"/>
<td align="left">rs12119179</td>
<td align="left">TACCCAGGGCATTCAGCTAC</td>
<td align="left">GCTTGAGCTCCTGGATCAAG</td>
<td align="center">701</td>
</tr>
<tr>
<td align="left"/>
<td align="left">rs924080</td>
<td align="left">GCACGTATGCCTTTTTGCATA</td>
<td align="left">ATTTGAATGTGCCTTGGCAT</td>
<td align="center">364</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<p><italic>bp, base pair; IL, interleukin; rs, reference SNP; SNP, single nucleotide polymorphism; TNF, tumor necrosis factor</italic>.</p>
</table-wrap-foot>
</table-wrap>
<p>After checking the quality and size of the PCR products by agarose gel (1.5%) electrophoresis, SNPs genotyping was performed by direct sequencing using the BigDye Terminator version 3.1 (BDT v3.1) Cycle Sequencing Kit, followed by capillary electrophoresis on an ABI 3100XL Genetic Analyzer, according to the manufacturer&#x02019;s recommendations (Applied Biosystems, Foster City, CA, USA) (Figure <xref ref-type="fig" rid="F1">1</xref>).</p>
<fig position="float" id="F1">
<label>Figure 1</label>
<caption><p><bold>Electropherogram of rs1800871 and rs1800872</bold>. rs, reference SNP; SNP, single nucleotide polymorphism.</p></caption>
<graphic xlink:href="fimmu-04-00342-g001.tif"/>
</fig>
</sec>
<sec id="S2-3">
<title>Statistical analysis</title>
<p>Comparisons of allele and genotype frequencies between groups (patients versus control subjects, and between the patient&#x02019;s groups according to different clinical features) were performed using the Chi-square or Fisher&#x02019;s exact tests. The association analysis was carried out by Odds ratio (OR) and corresponding 95% confidence interval (95% CI). Statistical analyses were performed using GraphPad Prism Version 5.04 (GraphPad Software, Inc., La Jolla, CA, USA) and Epi Info 2000 Version 1.0 for Windows (Epi Info, Atlanta, GA, USA) software.</p>
</sec>
</sec>
<sec id="S3">
<title>Results</title>
<p>Table <xref ref-type="table" rid="T2">2</xref> shows the description of the clinical characteristics of the patients with BD of the current study. The mean age (&#x000B1;SD) of the patients at disease onset was 26&#x02009;&#x000B1;&#x02009;11&#x02009;years. Predominant lesions were oral ulcers (100%), cutaneous lesions (86.27%), genital ulcers (82.35%), eye lesions (62.74%), and arthritis (58.82%).</p>
<table-wrap position="float" id="T2">
<label>Table 2</label>
<caption><p><bold>Clinical and demographic features of the Beh&#x000E7;et patients of the current study</bold>.</p></caption>
<table frame="hsides" rules="groups">
<thead>
<tr>
<th align="left">Characteristics</th>
<th align="left">Frequency (<italic>n</italic>&#x02009;&#x0003D;&#x02009;51)</th>
</tr>
</thead>
<tbody>
<tr>
<td align="left">Mean age at disease onset&#x02009;&#x000B1;&#x02009;SD (year)</td>
<td align="left">26&#x02009;&#x000B1;&#x02009;11</td>
</tr>
<tr>
<td align="left">Sex ratio M/F (%, <italic>n</italic>)</td>
<td align="left">56.9/43.1 (29/22)</td>
</tr>
<tr>
<td align="left">Oral ulcers (%, <italic>n</italic>)</td>
<td align="left">100 (51)</td>
</tr>
<tr>
<td align="left">Genital ulcers (%, <italic>n</italic>)</td>
<td align="left">82.4 (42)</td>
</tr>
<tr>
<td align="left">Cutaneous lesions (%, <italic>n</italic>)</td>
<td align="left">86.3 (44)</td>
</tr>
<tr>
<td align="left">Eye lesions (%, <italic>n</italic>)</td>
<td align="left">62.7 (32)</td>
</tr>
<tr>
<td align="left">Neurological symptoms (%, <italic>n</italic>)</td>
<td align="left">35.3 (18)</td>
</tr>
<tr>
<td align="left">Venous thrombosis (%, <italic>n</italic>)</td>
<td align="left">25.5 (13)</td>
</tr>
<tr>
<td align="left">Arthritis (%, <italic>n</italic>)</td>
<td align="left">58.8 (30)</td>
</tr>
<tr>
<td align="left">Multiplex family (%, <italic>n</italic>)</td>
<td align="left">35.3 (18)</td>
</tr>
<tr>
<td align="left">pediatric case (%, <italic>n</italic>)</td>
<td align="left">19.6 (10)</td>
</tr>
<tr>
<td align="left">consanguinity (%, <italic>n</italic>)</td>
<td align="left">43.1 (22)</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<p><italic>SD, standard deviation</italic>.</p>
</table-wrap-foot>
</table-wrap>
<p>The distribution of alleles and genotypes frequencies of <italic>IL10</italic> promoter SNPs c.-819C&#x02009;&#x0003E;&#x02009;T (rs1800871) and c.-592C&#x02009;&#x0003E;&#x02009;A (rs1800872) showed that the two SNPs were in total linkage disequilibrium in our sample. For this, reason the results of one SNP c.-819C&#x02009;&#x0003E;&#x02009;T will be considered (Table <xref ref-type="table" rid="T3">3</xref>).</p>
<table-wrap position="float" id="T3">
<label>Table 3</label>
<caption><p><bold>Allelic and genotypic frequencies of rs1800871 variant in BD patients and controls</bold>.</p></caption>
<table frame="hsides" rules="groups">
<thead>
<tr>
<th align="left">Alleles and genotypes</th>
<th align="center" colspan="2">Frequencies (%)<hr/></th>
<th align="center"><italic>p</italic></th>
</tr>
<tr>
<th align="left"/>
<th align="center">Controls (<italic>n</italic>&#x02009;&#x0003D;&#x02009;96)</th>
<th align="center">Cases (<italic>n</italic>&#x02009;&#x0003D;&#x02009;51)</th>
<th align="left"/>
</tr>
</thead>
<tbody>
<tr>
<td align="left">C</td>
<td align="center">141 (73.4)</td>
<td align="center">57 (55.9)</td>
<td align="center">0.003&#x0002A;&#x0002A;</td>
</tr>
<tr>
<td align="left">T</td>
<td align="center">51 (26.6)</td>
<td align="center">45 (44.1)</td>
<td align="center"/>
</tr>
<tr>
<td align="left">CC</td>
<td align="center">50 (52.1)</td>
<td align="center">17 (33.3)</td>
<td align="center">0.005&#x0002A;&#x0002A;</td>
</tr>
<tr>
<td align="left">CT</td>
<td align="center">41 (42.7)</td>
<td align="center">23 (45.1)</td>
<td align="center"/>
</tr>
<tr>
<td align="left">TT</td>
<td align="center">5 (5.2)</td>
<td align="center">11 (21.6)</td>
<td align="center"/>
</tr>
</tbody>
</table>
<table-wrap-foot>
<p><italic>BD, Beh&#x000E7;et&#x02019;s disease; SNP, single nucleotide polymorphism; rs, reference SNP. &#x0002A;&#x0002A;<italic>p</italic>&#x02009;&#x0003C;&#x02009;0.01</italic>.</p>
</table-wrap-foot>
</table-wrap>
<p>The allele frequencies were significantly different in patients compared to controls. As indicated in Table <xref ref-type="table" rid="T3">3</xref>, the frequencies of c.-819T (rs1800871) allele, and of the -819TT, -819CT (rs1800871) genotypes were significantly increased in patients than in controls (<italic>p</italic>&#x02009;&#x0003D;&#x02009;0.003 and <italic>p</italic>&#x02009;&#x0003D;&#x02009;0.005, respectively). Additionally, these SNPs was significantly associated with the disease (c.-819T; OR&#x02009;&#x0003D;&#x02009;2.18, 95% CI 1.28&#x02013;3.73, <italic>p</italic>&#x02009;&#x0003C;&#x02009;0.01; -819TT and -819CT, OR&#x02009;&#x0003D;&#x02009;2.17, 95% CI 1.01&#x02013;4.69, <italic>p</italic>&#x02009;&#x0003C;&#x02009;0.05) (Figure <xref ref-type="fig" rid="F2">2</xref>).</p>
<fig position="float" id="F2">
<label>Figure 2</label>
<caption><p><bold>Odds ratios for associations between <italic>IL10</italic> c.-819C&#x02009;&#x0003E;&#x02009;T, and -819TT, -819CT (rs1800871) with Beh&#x000E7;et&#x02019;s disease</bold>. The two SNPs c.-819C&#x02009;&#x0003E;&#x02009;T and c.-592C&#x02009;&#x0003E;&#x02009;A are in total linkage disequilibrium in our sample; therefore, the results of only one SNP c.-819C&#x02009;&#x0003E;&#x02009;T is considered. CI, confidence interval; rs, reference SNP; SNP, single nucleotide polymorphism.</p></caption>
<graphic xlink:href="fimmu-04-00342-g002.tif"/>
</fig>
<p>A subset analysis was performed to examine the difference in allele frequencies in clinical subsets of BD (Table <xref ref-type="table" rid="T4">4</xref>). We observed a significant association between c.-819T and all classes; nevertheless, the association was slightly lower for the ocular lesion (OR&#x02009;&#x0003D;&#x02009;1.55, 95% CI 0.81&#x02013;2.96, <italic>p</italic>&#x02009;&#x0003E;&#x02009;0.05). Additionally, the association was more significant for the Genital ulcers (OR&#x02009;&#x0003D;&#x02009;2.21; 95% CI 1.29&#x02013;4.04, <italic>p</italic>&#x02009;&#x0003D;&#x02009;0.002).</p>
<table-wrap position="float" id="T4">
<label>Table 4</label>
<caption><p><bold>Association analysis of clinical subclasses with <italic>IL10</italic> c.-819T SNP in patients with Beh&#x000E7;et&#x02019;s disease</bold>.</p></caption>
<table frame="hsides" rules="groups">
<thead>
<tr>
<th align="left">Clinical subset</th>
<th align="left">OR</th>
<th align="center" colspan="2">95% CI<hr/></th>
<th align="left"><italic>p</italic></th>
</tr>
<tr>
<th align="left"/>
<th align="left"/>
<th align="left">LL</th>
<th align="left">UL</th>
<th align="left"/>
</tr>
</thead>
<tbody>
<tr>
<td align="left">Eye disease</td>
<td align="left">1.55</td>
<td align="left">0.81</td>
<td align="left">2.96</td>
<td align="left">0.152</td>
</tr>
<tr>
<td align="left">Genital ulcers</td>
<td align="left">2.21</td>
<td align="left">1.29</td>
<td align="left">4.04</td>
<td align="left">0.002&#x0002A;&#x0002A;</td>
</tr>
<tr>
<td align="left">Skin lesions</td>
<td align="left">2.07</td>
<td align="left">1.17</td>
<td align="left">3.68</td>
<td align="left">0.007&#x0002A;&#x0002A;</td>
</tr>
<tr>
<td align="left">Arthritis-arthralgia</td>
<td align="left">2.06</td>
<td align="left">1.11</td>
<td align="left">3.81</td>
<td align="left">0.013&#x0002A;</td>
</tr>
<tr>
<td align="left">Neurologic signs</td>
<td align="left">2.5</td>
<td align="left">1.18</td>
<td align="left">5.32</td>
<td align="left">0.009&#x0002A;&#x0002A;</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<p><italic>CI, confidence interval; LL, lower limit; UP, upper limit; OR, odds ratio; SNP, single nucleotide polymorphism. &#x0002A;<italic>p</italic>&#x02009;&#x0003C;&#x02009;0.05, &#x0002A;&#x0002A;<italic>p</italic>&#x02009;&#x0003C;&#x02009;0.01</italic>.</p>
</table-wrap-foot>
</table-wrap>
<p>We reported in Tables <xref ref-type="table" rid="T5">5</xref> and <xref ref-type="table" rid="T6">6</xref> that all <italic>IL23R</italic>-<italic>IL12RB2</italic> SNPs alleles and genotypes, respectively, were not significantly associated with the disease (OR&#x02009;&#x0003E;&#x02009;1, <italic>p</italic>&#x02009;&#x0003E;&#x02009;0.05). The minor allele frequencies were different in the two groups, but this difference did not reach statistical significance (<italic>p</italic>&#x02009;&#x0003E;&#x02009;0.05).</p>
<table-wrap position="float" id="T5">
<label>Table 5</label>
<caption><p><bold><italic>IL23R</italic>-<italic>IL12RB2</italic> and <italic>TNF</italic>-&#x003B1; allelic frequencies in patients with Beh&#x000E7;et&#x02019;s disease</bold>.</p></caption>
<table frame="hsides" rules="groups">
<thead>
<tr>
<th align="left">Loci</th>
<th align="left">SNPs</th>
<th align="center" colspan="2">Alleles frequency (proportion, %)</th>
<th align="center">OR (95% CI)</th>
<th align="center"><italic>p</italic></th>
</tr>
</thead>
<tbody>
<tr>
<td align="left"><italic>IL23R</italic>-<italic>IL12RB2</italic></td>
<td align="left">rs12119179 (g.67747415A&#x02009;&#x0003E;&#x02009;C)</td>
<td align="center">A</td>
<td align="center">C</td>
<td align="center">1.24 (0.72&#x02013;2.13)</td>
<td align="center">0.415</td>
</tr>
<tr>
<td align="left"/>
<td align="left">Patients</td>
<td align="center">67 (65.7)</td>
<td align="center">35 (34.3)</td>
<td align="center"/>
</tr>
<tr>
<td align="left"/>
<td align="left">Controls</td>
<td align="center">135 (70.3)</td>
<td align="center">57 (29.7)</td>
<td align="center"/>
</tr>
<tr>
<td align="left"/>
<td align="left">rs11209032 (g.67740092G&#x02009;&#x0003E;&#x02009;A)</td>
<td align="center">G</td>
<td align="center">A</td>
<td align="center">1.18 (0.68&#x02013;2.03)</td>
<td align="center">0.530</td>
</tr>
<tr>
<td align="left"/>
<td align="left">Patients</td>
<td align="center">67 (65.7)</td>
<td align="center">35 (34.3)</td>
<td align="center"/>
</tr>
<tr>
<td align="left"/>
<td align="left">Controls</td>
<td align="center">133 (69.3)</td>
<td align="center">59 (30.7)</td>
<td align="center"/>
</tr>
<tr>
<td align="left"/>
<td align="left">rs924080 (g.67760140T&#x02009;&#x0003E;&#x02009;C)</td>
<td align="center">T</td>
<td align="center">C</td>
<td align="center">1.45 (0.87&#x02013;2.41)</td>
<td align="center">0.133</td>
</tr>
<tr>
<td align="left"/>
<td align="left">Patients</td>
<td align="center">54 (52.9)</td>
<td align="center">48 (47.1)</td>
<td align="center"/>
</tr>
<tr>
<td align="left"/>
<td align="left">Controls</td>
<td align="center">84 (43.8)</td>
<td align="center">108 (56.3)</td>
<td align="center"/>
</tr>
<tr>
<td align="left"><italic>TNF</italic>-&#x003B1;</td>
<td align="left">rs1799964 (c.-1211T&#x02009;&#x0003E;&#x02009;C)</td>
<td align="center">T</td>
<td align="center">C</td>
<td align="center">0.92 (0.52&#x02013;1.61)</td>
<td align="center">0.751</td>
</tr>
<tr>
<td align="left"/>
<td align="left">Patients</td>
<td align="center">73 (71.6)</td>
<td align="center">29 (28.4)</td>
<td align="center"/>
</tr>
<tr>
<td align="left"/>
<td align="left">Controls</td>
<td align="center">134 (69.8)</td>
<td align="center">58 (30.2)</td>
<td align="center"/>
</tr>
<tr>
<td align="left"/>
<td align="left">rs1800630 (c.-1043C&#x02009;&#x0003E;&#x02009;A)</td>
<td align="center">C</td>
<td align="center">A</td>
<td align="center">0.83 (0.41&#x02013;1.67)</td>
<td align="center">0.584</td>
</tr>
<tr>
<td align="left"/>
<td align="left">Patients</td>
<td align="center">86 (84.3)</td>
<td align="center">16 (15.7)</td>
<td align="center"/>
</tr>
<tr>
<td align="left"/>
<td align="left">Controls</td>
<td align="center">157 (81.8)</td>
<td align="center">35 (18.2)</td>
<td align="center"/>
</tr>
<tr>
<td align="left"/>
<td align="left">rs17999724 (c.-1037C&#x02009;&#x0003E;&#x02009;T)</td>
<td align="center">C</td>
<td align="center">T</td>
<td align="center">1.01 (0.35&#x02013;2.84)</td>
<td align="center">0.976</td>
</tr>
<tr>
<td align="left"/>
<td align="left">Patients</td>
<td align="center">95 (93.1)</td>
<td align="center">7 (6.9)</td>
<td align="center"/>
</tr>
<tr>
<td align="left"/>
<td align="left">Controls</td>
<td align="center">179&#x02009;(93.3)</td>
<td align="center">13 (6.7)</td>
<td align="center"/>
</tr>
<tr>
<td align="left"/>
<td align="left">rs1800750 (c.-556G&#x02009;&#x0003E;&#x02009;A)</td>
<td align="center">G</td>
<td align="center">A</td>
<td align="center">0.61 (0.14&#x02013;2.09)</td>
<td align="center">0.402</td>
</tr>
<tr>
<td align="left"/>
<td align="left">Patients</td>
<td align="center">98 (96.1)</td>
<td align="center">4 (3.9)</td>
<td align="center"/>
</tr>
<tr>
<td align="left"/>
<td align="left">Controls</td>
<td align="center">180 (93.7)</td>
<td align="center">12 (6.3)</td>
<td align="center"/>
</tr>
<tr>
<td align="left"/>
<td align="left">rs1800629 (c.-488G&#x02009;&#x0003E;&#x02009;A)</td>
<td align="center">G</td>
<td align="center">A</td>
<td align="center">1.12 (0.56&#x02013;2.26)</td>
<td align="center">0.726</td>
</tr>
<tr>
<td align="left"/>
<td align="left">Patients</td>
<td align="center">85 (83.3)</td>
<td align="center">17 (16.7)</td>
<td align="center"/>
</tr>
<tr>
<td align="left"/>
<td align="left">Controls</td>
<td align="center">163 (84.9)</td>
<td align="center">29 (15.1)</td>
<td align="center"/>
</tr>
<tr>
<td align="left"/>
<td align="left">rs361525 (c.-418G&#x02009;&#x0003E;&#x02009;A)</td>
<td align="center">G</td>
<td align="center">A</td>
<td align="center">0.93 (0.39&#x02013;2.21)</td>
<td align="center">0.869</td>
</tr>
<tr>
<td align="left"/>
<td align="left">Patients</td>
<td align="center">92 (90.2)</td>
<td align="center">10 (9.8)</td>
<td align="center"/>
</tr>
<tr>
<td align="left"/>
<td align="left">Controls</td>
<td align="center">172 (89.6)</td>
<td align="center">20 (10.4)</td>
<td align="center"/>
</tr>
</tbody>
</table>
<table-wrap-foot>
<p><italic>CI, confidence interval; <italic>IL23R</italic>-<italic>IL12RB2</italic>, region of the interleukin-23 receptor and interleukin-12 receptor beta 2 chain-encoding gene; OR, odds ratio; rs, reference SNP; SNP, single nucleotide polymorphism; TNF, tumor necrosis factor</italic>.</p>
</table-wrap-foot>
</table-wrap>
<table-wrap position="float" id="T6">
<label>Table 6</label>
<caption><p><bold>The distribution of <italic>IL23R</italic>-<italic>IL12RB2</italic> genotypes in patients with Beh&#x000E7;et disease</bold>.</p></caption>
<table frame="hsides" rules="groups">
<thead>
<tr>
<th align="left">SNPs</th>
<th align="center" colspan="3">Genotype distribution (frequency, %)</th>
<th align="center"><italic>p</italic>-Value</th>
<th align="center">OR (95% CI) <italic>p</italic>-value</th>
<th align="center">MAF (%)</th>
<th align="center">OR<sup>MAF</sup> (95% CI) <italic>p</italic>-value</th>
</tr>
</thead>
<tbody>
<tr>
<td align="left">rs12119179 (g.67747415A&#x02009;&#x0003E;&#x02009;C)</td>
<td align="center">AA</td>
<td align="center">AC</td>
<td align="center">CC</td>
<td align="center">0.522</td>
<td align="center">1.13 (0.54&#x02013;2.35) 0.734</td>
<td align="center">C</td>
<td align="center">1.24 (0.58&#x02013;2.67) 0.580</td>
</tr>
<tr>
<td align="left">Patients</td>
<td align="center">24 (47.1)</td>
<td align="center">19 (37.2)</td>
<td align="center">8 (15.7)</td>
<td align="center"/>
<td align="center"/>
<td align="center">34.31</td>
<td align="center"/>
</tr>
<tr>
<td align="left">Controls</td>
<td align="center">48 (50)</td>
<td align="center">39 (40.6)</td>
<td align="center">9 (9.4)</td>
<td align="center"/>
<td align="center"/>
<td align="center">29.69</td>
<td align="center"/>
</tr>
<tr>
<td align="left">rs11209032 (g.67740092G&#x02009;&#x0003E;&#x02009;A)</td>
<td align="center">GG</td>
<td align="center">GA</td>
<td align="center">AA</td>
<td align="center">0.721</td>
<td align="center">1.12 (0.57&#x02013;2.21) 0.744</td>
<td align="center">A</td>
<td align="center">1.18 (0.71&#x02013;1.97) 0.560</td>
</tr>
<tr>
<td align="left">Patients</td>
<td align="center">23 (45.1)</td>
<td align="center">21 (41.2)</td>
<td align="center">7 (13.7)</td>
<td align="center"/>
<td align="center"/>
<td align="center">34.31</td>
<td align="center"/>
</tr>
<tr>
<td align="left">Controls</td>
<td align="center">46 (47.9)</td>
<td align="center">41 (42.7)</td>
<td align="center">9 (9.4)</td>
<td align="center"/>
<td align="center"/>
<td align="center">30.73</td>
<td align="center"/>
</tr>
<tr>
<td align="left">rs924080 (g.67760140T&#x02009;&#x0003E;&#x02009;C)</td>
<td align="center">CC</td>
<td align="center">CT</td>
<td align="center">TT</td>
<td align="center">0.327</td>
<td align="center">1.46 (0.64&#x02013;3.35) 0.326</td>
<td align="center">C</td>
<td align="center">1.58 (0.71&#x02013;3.54) 0.264</td>
</tr>
<tr>
<td align="left">Patients</td>
<td align="center">13 (25.5)</td>
<td align="center">22 (43.1)</td>
<td align="center">16 (31.4)</td>
<td align="center"/>
<td align="center"/>
<td align="center">47.1</td>
<td align="center"/>
</tr>
<tr>
<td align="left">Controls</td>
<td align="center">32 (33.4)</td>
<td align="center">44 (45.8)</td>
<td align="center">20 (20.8)</td>
<td align="center"/>
<td align="center"/>
<td align="center">56.25</td>
<td align="center"/>
</tr>
</tbody>
</table>
<table-wrap-foot>
<p><italic>ORs were calculated for the minor versus major alleles. CI, confidence interval; <italic>IL23R</italic>-<italic>IL12RB2</italic>, interleukin-23 receptor and interleukin-12 receptor beta 2 chain-encoding gene; MAF, minor allele frequency; OR<sup>MAF</sup>, OR of the MAF; OR, odds ratio; rs, reference SNP; SNP, single nucleotide polymorphism</italic>.</p>
</table-wrap-foot>
</table-wrap>
<p>As indicated in Tables <xref ref-type="table" rid="T5">5</xref> and <xref ref-type="table" rid="T7">7</xref>, alleles and genotypes of the <italic>TNF</italic>-&#x003B1; polymorphisms display similar distributions in patients and controls (<italic>p</italic>&#x02009;&#x0003E;&#x02009;0.05). Except for c.-1037T and c.-488A all others <italic>TNF</italic>-&#x003B1; alleles were not associated with BD (OR&#x02009;&#x0003C;&#x02009;1).</p>
<table-wrap position="float" id="T7">
<label>Table 7</label>
<caption><p><bold>The distribution of <italic>TNF</italic>-&#x003B1; genotypes in patients with Beh&#x000E7;et disease</bold>.</p></caption>
<table frame="hsides" rules="groups">
<thead>
<tr>
<th align="left">SNPs</th>
<th align="center" colspan="3">Genotype distribution (frequency, %)</th>
<th align="center"><italic>p</italic>-Value</th>
<th align="center">OR (95% CI) <italic>p</italic>-value</th>
<th align="center">MAF (%)</th>
<th align="center">OR<sup>MAF</sup> (95% CI) <italic>p</italic>-value</th>
</tr>
</thead>
<tbody>
<tr>
<td align="left">rs1799964 (c.-1211T&#x02009;&#x0003E;&#x02009;C)</td>
<td align="center">TT</td>
<td align="center">TC</td>
<td align="center">CC</td>
<td align="center">0.114</td>
<td align="center">0.67 (0.32&#x02013;1.4) 0.249</td>
<td align="center">C</td>
<td align="center">0.8 (0.37&#x02013;1.75) 0.580</td>
</tr>
<tr>
<td align="left">Patients</td>
<td align="center">29 (56.9)</td>
<td align="center">15 (29.4)</td>
<td align="center">7 (13.7)</td>
<td align="center"/>
<td align="center"/>
<td align="center">28.43</td>
<td align="center"/>
</tr>
<tr>
<td align="left">Controls</td>
<td align="center">45 (46.9)</td>
<td align="center">44 (45.8)</td>
<td align="center">7 (7.29)</td>
<td align="center"/>
<td align="center"/>
<td align="center">30.21</td>
<td align="center"/>
</tr>
<tr>
<td align="left">rs1800630 (c.-1043C&#x02009;&#x0003E;&#x02009;A)</td>
<td align="center">CC</td>
<td align="center">CA</td>
<td align="center">AA</td>
<td align="center">0.826</td>
<td align="center">0.79 (0.35&#x02013;1.78) 0.544</td>
<td align="center">A</td>
<td align="center">0.78 (0.31&#x02013;1.97) 0.600</td>
</tr>
<tr>
<td align="left">Patients</td>
<td align="center">37 (72.5)</td>
<td align="center">12 (23.5)</td>
<td align="center">2 (4)</td>
<td align="center"/>
<td align="center"/>
<td align="center">15.69</td>
<td align="center"/>
</tr>
<tr>
<td align="left">Controls</td>
<td align="center">65 (67.7)</td>
<td align="center">27 (28.1)</td>
<td align="center">4 (4.2)</td>
<td align="center"/>
<td align="center"/>
<td align="center">18.23</td>
<td align="center"/>
</tr>
<tr>
<td align="left">rs17999724 (c.-1037C&#x02009;&#x0003E;&#x02009;T)</td>
<td align="center">CC</td>
<td align="center">CT</td>
<td align="center">TT</td>
<td align="center">ND</td>
<td align="center">1.23 (0.4&#x02013;3.74) 0.690</td>
<td align="center">T</td>
<td align="center">1.26 (0.34&#x02013;4.69) 0.733</td>
</tr>
<tr>
<td align="left">Patients</td>
<td align="center">44 (86.3)</td>
<td align="center">7 (13.7)</td>
<td align="center">0 (0)</td>
<td align="center"/>
<td align="center"/>
<td align="center">6.86</td>
<td align="center"/>
</tr>
<tr>
<td align="left">Controls</td>
<td align="center">83 (86.5)</td>
<td align="center">13 (13.5)</td>
<td align="center">0 (0)</td>
<td align="center"/>
<td align="center"/>
<td align="center">6.77</td>
<td align="center"/>
</tr>
<tr>
<td align="left">rs1800750 (c.-556G&#x02009;&#x0003E;&#x02009;A)</td>
<td align="center">GG</td>
<td align="center">GA</td>
<td align="center">AA</td>
<td align="center">ND</td>
<td align="center">0.6 (0.13&#x02013;2.12) 0.388</td>
<td align="center">A</td>
<td align="center">0.6 (0.12&#x02013;3.07) 0.536</td>
</tr>
<tr>
<td align="left">Patients</td>
<td align="center">47 (92.2)</td>
<td align="center">4 (7.8)</td>
<td align="center">0 (0)</td>
<td align="center"/>
<td align="center"/>
<td align="center">3.92</td>
<td align="center"/>
</tr>
<tr>
<td align="left">Controls</td>
<td align="center">84 (87.5)</td>
<td align="center">12 (12.5)</td>
<td align="center">0 (0)</td>
<td align="center"/>
<td align="center"/>
<td align="center">6.25</td>
<td align="center"/>
</tr>
<tr>
<td align="left">rs1800629 (c.-488G&#x02009;&#x0003E;&#x02009;A)</td>
<td align="center">GG</td>
<td align="center">GA</td>
<td align="center">AA</td>
<td align="center">0.909</td>
<td align="center">1.17 (0.52&#x02013;2.61) 0.680</td>
<td align="center">A</td>
<td align="center">1.18 (0.47&#x02013;2.97) 0.721</td>
</tr>
<tr>
<td align="left">Patients</td>
<td align="center">35 (68.6)</td>
<td align="center">15 (29.4)</td>
<td align="center">1 (2)</td>
<td align="center"/>
<td align="center"/>
<td align="center">16.67</td>
<td align="center"/>
</tr>
<tr>
<td align="left">Controls</td>
<td align="center">69 (71.9)</td>
<td align="center">25 (26)</td>
<td align="center">2 (2.1)</td>
<td align="center"/>
<td align="center"/>
<td align="center">15.1</td>
<td align="center"/>
</tr>
<tr>
<td align="left">rs361525 (c.-418G&#x02009;&#x0003E;&#x02009;A)</td>
<td align="center">GG</td>
<td align="center">GA</td>
<td align="center">AA</td>
<td align="center">0.299</td>
<td align="center">0.75 (0.28&#x02013;2.02) 0.541</td>
<td align="center">A</td>
<td align="center">0.9 (0.29&#x02013;2.79) 0.849</td>
</tr>
<tr>
<td align="left">Patients</td>
<td align="center">43 (84.3)</td>
<td align="center">6 (11.8)</td>
<td align="center">2 (3.9)</td>
<td align="center"/>
<td align="center"/>
<td align="center">9.8</td>
<td align="center"/>
</tr>
<tr>
<td align="left">Controls</td>
<td align="center">77 (80.2)</td>
<td align="center">18 (18.8)</td>
<td align="center">1 (1)</td>
<td align="center"/>
<td align="center"/>
<td align="center">10.42</td>
<td align="center"/>
</tr>
</tbody>
</table>
<table-wrap-foot>
<p><italic>ORs were calculated for the minor versus major alleles. CI, confidence interval; MAF, minor allele frequency; ND, not defined; OR, odds ratio; OR<sup>MAF</sup>, OR of the MAF; rs, reference SNP; SNP, single nucleotide polymorphism; TNF, tumor necrosis factor</italic>.</p>
</table-wrap-foot>
</table-wrap>
</sec>
<sec id="S4" sec-type="discussion">
<title>Discussion</title>
<p>To date, the etiopathogenesis of BD is not fully elucidated. Researches in recent decades have shown the complex role of genetic factors in the development of the disease. We analyze the association between BD and 11 SNPs in <italic>IL10, TNF</italic>-&#x003B1;, and <italic>IL23R</italic>-<italic>IL12RB2</italic> candidate genes in the Western Algeria population.</p>
<p>This is the first report demonstrating that the c.-819T and c.-592A alleles were associated with BD in Algeria.</p>
<p>Previous genetic studies have shown a strong association of many <italic>IL10</italic> variants with BD in different ethnic groups. Recent genome-wide association study conducted by Mizuki et al. (<xref ref-type="bibr" rid="B14">14</xref>) in a Japanese cohort, including 612 individuals with BD and 740 unaffected individuals controls from different ethnic groups, has shown a significant difference between the two groups for five <italic>IL10</italic> SNPs. The two SNPs analyzed in our study showed an association (OR&#x02009;&#x0003D;&#x02009;2.18, 95% CI 1.28&#x02013;3.73, <italic>p</italic>&#x02009;&#x0003C;&#x02009;0.01). On the other hand, a strong association has also been highlighted for <italic>IL10</italic> rs1518111 (OR&#x02009;&#x0003D;&#x02009;1.45, 95% CI 1.34&#x02013;1.58) in a genome-wide study performed in 311,459 SNPs in 1215 individuals with BD and 1278 healthy controls from Turkey (<xref ref-type="bibr" rid="B13">13</xref>). Our results are consistent with those obtained by Wallace et al. (<xref ref-type="bibr" rid="B38">38</xref>) who studied the segregation of two <italic>IL10</italic> promoter SNPs, rs1800871 and rs1800896 in 178 cases and 295 controls from two populations, including Arab Middle East and United Kingdom. A strong association of the 819T allele has been observed in United Kingdom patients (OR 1.5, 95% CI 1.1&#x02013;2).</p>
<p>Our results are, however, in disagreement with those of the study of Ates et al. (<xref ref-type="bibr" rid="B39">39</xref>) in which no significant association was revealed by exploring three <italic>IL10</italic> SNPs (-1082G&#x02009;&#x0003E;&#x02009;A, rs1800896, c.-819C&#x02009;&#x0003E;&#x02009;T, rs1800871, and c.-592C&#x02009;&#x0003E;&#x02009;A, rs1800872) in 102 patients with BD and 102 controls from Turkey. These conflicting results may be explained by ethnic differences.</p>
<p>Several studies have shown the association of the two (c.-819 C&#x02009;&#x0003E;&#x02009;T, c.-592C&#x02009;&#x0003E;&#x02009;A) studied SNPs with various inflammatory diseases, but also with cancer (<xref ref-type="bibr" rid="B51">51</xref>&#x02013;<xref ref-type="bibr" rid="B53">53</xref>), periodontitis (<xref ref-type="bibr" rid="B54">54</xref>), and docetaxel-induced liver injury (<xref ref-type="bibr" rid="B55">55</xref>). These associations suggested that the two SNPs can play an important role in the expression of <italic>IL10</italic>. In fact, it has been previously reported that the SNP c.-819C&#x02009;&#x0003E;&#x02009;T and/or c.-592C&#x02009;&#x0003E;&#x02009;A alleles affect the transcription of <italic>IL10</italic> (<xref ref-type="bibr" rid="B56">56</xref>). Other studies performed on three SNPs at position -1082 A&#x02009;&#x0003E;&#x02009;G, -819C&#x02009;&#x0003E;&#x02009;T, and -592C&#x02009;&#x0003E;&#x02009;A in the promoter region of the <italic>IL10</italic> gene have shown that the expression levels of IL-10 was significantly different according to the some haplotypes (<xref ref-type="bibr" rid="B57">57</xref>, <xref ref-type="bibr" rid="B58">58</xref>). Finally, it has been reported that the disease-associated rs1518111 allele seems to be associated with low IL-10 mRNA expression and protein production (<xref ref-type="bibr" rid="B13">13</xref>). Indeed at the SNP rs1518111 locus, the rate of transcript of the G allele is higher than that of the A allele and patients homozygous for the A allele produce less IL-10 than those who are heterozygous or homozygous for the G allele.</p>
<p>The result of subset analysis suggests that the risk allele might predispose to genital ulcers, skin lesions, neurologic signs, and arthritis-arthralgia, but weakly to eye complications; the association was more significant for the genital ulcers (OR&#x02009;&#x0003D;&#x02009;2.21, <italic>p</italic>&#x02009;&#x0003D;&#x02009;0.002). Our results are in agreement with those of previous study (<xref ref-type="bibr" rid="B21">21</xref>) that showed a variable increase in mRNA expression within all BD lesions, including oral and genital ulcers, pseudofolliculitis lesions, and lesions at the site of pathergy testing.</p>
<p>Recent GWAS study from Turkey and Japan revealed <italic>IL12R</italic>-<italic>IL23RB2</italic> SNPs in association with BD. Three SNPs were strongly associated with the disease, including rs924080 (OR&#x02009;&#x0003D;&#x02009;1.28, <italic>p</italic>&#x02009;&#x0003D;&#x02009;6.69&#x02009;&#x000D7;&#x02009;10<sup>&#x02212;9</sup>) (<xref ref-type="bibr" rid="B13">13</xref>), rs12119179 (<italic>p</italic>&#x02009;&#x0003D;&#x02009;2.7&#x02009;&#x000D7;&#x02009;10<sup>&#x02212;8</sup>), and rs1495965 (OR&#x02009;&#x0003D;&#x02009;1.35, <italic>p</italic>&#x02009;&#x0003D;&#x02009;1.9&#x02009;&#x000D7;&#x02009;10<sup>&#x02212;11</sup>) (<xref ref-type="bibr" rid="B14">14</xref>), but no significant association was found in a Korean cohort.</p>
<p>Our results showed no significant association between BD and rs12119179, g.67740092G&#x02009;&#x0003E;&#x02009;A (rs11209032), and g.67760140T&#x02009;&#x0003E;&#x02009;C (rs924080) SNPs in the <italic>IL23R</italic>-<italic>IL12RB2</italic> region. In Iranian study (<xref ref-type="bibr" rid="B59">59</xref>), six SNPs in <italic>IL23R</italic>-<italic>IL12RB2</italic> were found to be associated with BD; the most significant of which were rs17375018 (OR&#x02009;&#x0003D;&#x02009;1.51, <italic>p</italic>&#x02009;&#x0003D;&#x02009;1.93&#x02009;&#x000D7;&#x02009;10<sup>&#x02212;6</sup>), rs7517847 (OR&#x02009;&#x0003D;&#x02009;1.48, <italic>p</italic>&#x02009;&#x0003D;&#x02009;1.23&#x02009;&#x000D7;&#x02009;10<sup>&#x02212;6</sup>), and rs924080 (OR&#x02009;&#x0003D;&#x02009;1.29, <italic>p</italic>&#x02009;&#x0003D;&#x02009;1.78&#x02009;&#x000D7;&#x02009;10<sup>&#x02212;5</sup>). Others studies have also identified a strong relationship between polymorphisms of <italic>IL23R</italic> and BD (<xref ref-type="bibr" rid="B60">60</xref>&#x02013;<xref ref-type="bibr" rid="B62">62</xref>). These associations may suggest an important role of Th17 cells that express the IL-23R on their surface. Kim et al. (<xref ref-type="bibr" rid="B62">62</xref>) studied the interaction of specific <italic>IL17A, IL23R</italic>, and STAT4 (signal transducers and activators of transcription 4) SNPs in intestinal BD Korean patients; they suggest that the IL-23/IL-17 axis plays a significant role in disease pathogenesis.</p>
<p>IL-12 has been implicated in the pathogenesis of a multitude of diverse autoimmune diseases (<xref ref-type="bibr" rid="B63">63</xref>, <xref ref-type="bibr" rid="B64">64</xref>). <italic>IL12RB2</italic> constitute a risk factor for primary biliary cirrhosis, with the reported top associated SNPs mainly located in intronic sequences (<xref ref-type="bibr" rid="B65">65</xref>&#x02013;<xref ref-type="bibr" rid="B67">67</xref>).</p>
<p>The genetic architecture and modularity of human autoimmune diseases is very complex. The functional implications of most of these associations are not yet clarified. Identify candidate causal SNPs and pathways (ICSN Pathway) analysis may act as a powerful guide to further research into the functional and immunological ramifications of these associations.</p>
<p>No significant associations were found between BD and studied <italic>TNF</italic>-&#x003B1; polymorphisms. These SNPs have been studied in various ethnic groups for possible association with BD. However, the allelic and genotypic associations of these studies have been contradictory. In Korean patients, <italic>TNF</italic>-&#x003B1; c.-1043A (rs1800630) allele was associated with an increased risk of BD (OR&#x02009;&#x0003D;&#x02009;1.4, <italic>p</italic>&#x02009;&#x0003D;&#x02009;0.030) (<xref ref-type="bibr" rid="B68">68</xref>). However, no significant association was found in meta-analysis studies for this SNP (<xref ref-type="bibr" rid="B42">42</xref>). Additionally, it has been reported a significant associations between c.-1037T allele (rs1799724) (OR&#x02009;&#x0003D;&#x02009;0.76, 95% CI 0.58&#x02013;0.98), c.-488G allele (rs1800629) (OR&#x02009;&#x0003D;&#x02009;1.8, <italic>p</italic>&#x02009;&#x0003D;&#x02009;0.010) (<xref ref-type="bibr" rid="B68">68</xref>), and c.-418A allele (rs361525) (OR&#x02009;&#x0003D;&#x02009;1.51, 95% CI 1.12&#x02013;2.04) (<xref ref-type="bibr" rid="B42">42</xref>), and BD. Moreover, no significant associations were identified with other <italic>TNF</italic>-&#x003B1; promoter polymorphisms, such as c.-1037T (rs1799724), c.-488A (rs1800629), and c.-556G&#x02009;&#x0003E;&#x02009;A (rs1800750) alleles with BD in Moroccan patients (<xref ref-type="bibr" rid="B43">43</xref>). The <italic>TNF</italic>-&#x003B1; c.-1211C allele (rs1799964) presented a significant association with BD in several populations, including Turkish (<italic>p</italic>&#x02009;&#x0003D;&#x02009;0.023) (<xref ref-type="bibr" rid="B69">69</xref>), Korean (<italic>p</italic>&#x02009;&#x0003D;&#x02009;0.030, OR&#x02009;&#x0003D;&#x02009;1.4) (<xref ref-type="bibr" rid="B68">68</xref>), and UK white Caucasoid population (RR&#x02009;&#x0003D;&#x02009;2.3, <italic>p</italic>&#x02009;&#x0003D;&#x02009;0.00004) (<xref ref-type="bibr" rid="B40">40</xref>). The frequency of the <italic>TNF</italic>-&#x003B1; c.-1211C allele was significantly higher in Behcet&#x02019;s patients than in healthy controls in Moroccan and Tunisian populations (OR&#x02009;&#x0003D;&#x02009;1.65, <italic>p</italic>&#x02009;&#x0003D;&#x02009;0.015; OR&#x02009;&#x0003D;&#x02009;1.68, <italic>p</italic>&#x02009;&#x0003D;&#x02009;0.02, respectively) (<xref ref-type="bibr" rid="B41">41</xref>, <xref ref-type="bibr" rid="B43">43</xref>) and in meta-analysis (OR&#x02009;&#x0003D;&#x02009;1.35, 95% CI 1.09&#x02013;1.68) (<xref ref-type="bibr" rid="B42">42</xref>). This polymorphism has been associated with several extra-intestinal manifestations of Crohn&#x02019;s disease, including uveitis, erythema nodosum, and large joint arthropathy (<xref ref-type="bibr" rid="B70">70</xref>), all of which are known to be associated with BD. Further investigation is necessary to determine the functional significance of <italic>TNF</italic>-&#x003B1; c.-1691042C and how it participates in the inflammatory dysregulation associated with BD.</p>
<p>Thus, polymorphisms at positions c.-1211T&#x02009;&#x0003E;&#x02009;C, c.-1043C&#x02009;&#x0003E;&#x02009;A, c.-1037C&#x02009;&#x0003E;&#x02009;T, and c.-488G&#x02009;&#x0003E;&#x02009;A have been associated with increased transcriptional activity and production of TNF-&#x003B1; in some studies (<xref ref-type="bibr" rid="B37">37</xref>, <xref ref-type="bibr" rid="B71">71</xref>), in contrast to others (<xref ref-type="bibr" rid="B72">72</xref>&#x02013;<xref ref-type="bibr" rid="B75">75</xref>). The over production of TNF-&#x003B1; during the course of BD may result in other <italic>TNF</italic>-&#x003B1; polymorphisms or post-transcriptional mechanisms. Furthermore, TNF-&#x003B1; production is not only under the control of the promoter region of <italic>TNF</italic>-&#x003B1;, and it may also result from complex cis and trans interactions among other cytokines.</p>
<p><italic>TNF</italic>-&#x003B1; is encoded in the HLA complex on chromosome 6, a region that has long been known to be associated with BD. This gene-dense region, presentes a strong linkage disequilibrium (<xref ref-type="bibr" rid="B76">76</xref>). The association between BD and <italic>TNF</italic>-&#x003B1; could therefore be a result of linkage disequilibrium with alleles within this group. So it will be interesting to investigate other genes polymorphism among this region in our population.</p>
<p>In conclusion, we replicate the associations between BD and the SNPs from the <italic>IL23R</italic>-<italic>IL12RB2</italic> region and c.-1037C&#x02009;&#x0003E;&#x02009;T and c.-488G&#x02009;&#x0003E;&#x02009;A <italic>TNF</italic>-&#x003B1; promoter SNPs. <italic>IL10</italic> promoter SNPs (rs1800871 and rs1800872) is strongly associated with BD in the population of the Western Algeria. It would be interesting to study other SNPs to identify additional associations with BD in the studied population.</p>
</sec>
<sec id="S5">
<title>Authors Contribution</title>
<p>Mourad Aribi, G&#x000E9;rard Lefranc are Principal Investigators of the study, participated in its design and execution and helped draft the manuscript and critically reviewed it for intellectual content; Mouna Barat-Houari participated in the design of the study, carried out genetic analyses, and helped draft the manuscript; Ouahiba Khaib Dit Naib wrote the manuscript and carried out genetic analyses; Aicha Idder, Amel Chiali, and Hakim Sairi are responsible for the recruitment of eligible patients and their families; Isabelle Touitou conceived of the study, participated in its design, and coordination. All the authors read and approved the final manuscript.</p>
</sec>
<sec id="S6">
<title>Conflict of Interest Statement</title>
<p>The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.</p>
</sec>
</body>
<back>
<ack>
<p>The authors are grateful to the patients, their families and the healthy controls for their participation. They would also like to address special thanks to Nathalie Ruiz-Pallares, Department of Genetics, CHRU, Montpellier, and all the staff of the Oran Blood Transfusion Centre for their help during this study.</p>
</ack>
<ref-list>
<title>References</title>
<ref id="B1"><label>1</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>McGonagle</surname> <given-names>D</given-names></name> <name><surname>McDermott</surname> <given-names>MF</given-names></name></person-group>. <article-title>A proposed classification of the immunological diseases</article-title>. <source>PLoS Med</source> (<year>2006</year>) <volume>3</volume>:<fpage>e297</fpage>.<pub-id pub-id-type="doi">10.1371/journal.pmed.0030297</pub-id></citation></ref>
<ref id="B2"><label>2</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Krause</surname> <given-names>I</given-names></name> <name><surname>Weinberger</surname> <given-names>A</given-names></name></person-group>. <article-title>Beh&#x000E7;et&#x02019;s disease</article-title>. <source>Curr Opin Rheumatol</source> (<year>2008</year>) <volume>20</volume>:<fpage>82</fpage>&#x02013;<lpage>7</lpage>.<pub-id pub-id-type="doi">10.1097/BOR.0b013e3282f154d1</pub-id></citation></ref>
<ref id="B3"><label>3</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Suzuki Kurokawa</surname> <given-names>M</given-names></name> <name><surname>Suzuki</surname> <given-names>N</given-names></name></person-group>. <article-title>Behcet&#x02019;s disease</article-title>. <source>Clin Exp Med</source> (<year>2004</year>) <volume>4</volume>:<fpage>10</fpage>&#x02013;<lpage>20</lpage>.<pub-id pub-id-type="doi">10.1007/s10238-004-0033-4</pub-id></citation></ref>
<ref id="B4"><label>4</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Yazici</surname> <given-names>H</given-names></name> <name><surname>Esen</surname> <given-names>F</given-names></name></person-group>. <article-title>Mortality in Beh&#x000E7;et&#x02019;s syndrome</article-title>. <source>Clin Exp Rheumatol</source> (<year>2008</year>) <volume>26</volume>(<issue>Suppl 51</issue>):<fpage>S138</fpage>&#x02013;<lpage>40</lpage>.</citation></ref>
<ref id="B5"><label>5</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Fietta</surname> <given-names>P</given-names></name></person-group>. <article-title>Beh&#x000E7;et&#x02019;s disease: familial clustering and immunogenetics</article-title>. <source>Clin Exp Rheumatol</source> (<year>2005</year>) <volume>23</volume>(<issue>Suppl 38</issue>):<fpage>S96</fpage>&#x02013;<lpage>105</lpage>.<pub-id pub-id-type="pmid">16273774</pub-id></citation></ref>
<ref id="B6"><label>6</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>de Menthon</surname> <given-names>M</given-names></name> <name><surname>Lavalley</surname> <given-names>MP</given-names></name> <name><surname>Maldini</surname> <given-names>C</given-names></name> <name><surname>Guillevin</surname> <given-names>L</given-names></name> <name><surname>Mahr</surname> <given-names>A</given-names></name></person-group>. <article-title>HLA-B51/B5 and the risk of Beh&#x000E7;et&#x02019;s disease: a systematic review and meta-analysis of case-control genetic association studies</article-title>. <source>Arthritis Rheum</source> (<year>2009</year>) <volume>61</volume>:<fpage>1287</fpage>&#x02013;<lpage>96</lpage>.<pub-id pub-id-type="doi">10.1002/art.24642</pub-id><pub-id pub-id-type="pmid">19790126</pub-id></citation></ref>
<ref id="B7"><label>7</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Ohno</surname> <given-names>S</given-names></name> <name><surname>Aoki</surname> <given-names>K</given-names></name> <name><surname>Sugiura</surname> <given-names>S</given-names></name> <name><surname>Nakayama</surname> <given-names>E</given-names></name> <name><surname>Itakura</surname> <given-names>K</given-names></name> <name><surname>Aizawa</surname> <given-names>M</given-names></name></person-group>. <article-title>HLA-B5 and Beh&#x000E7;et&#x02019;s disease</article-title>. <source>Lancet</source> (<year>1973</year>) <volume>302</volume>:<fpage>1383</fpage>&#x02013;<lpage>4</lpage>.<pub-id pub-id-type="doi">10.1016/S0140-6736(73)93343-6</pub-id></citation></ref>
<ref id="B8"><label>8</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Ohno</surname> <given-names>S</given-names></name> <name><surname>Ohguchi</surname> <given-names>M</given-names></name> <name><surname>Hirose</surname> <given-names>S</given-names></name> <name><surname>Matsuda</surname> <given-names>H</given-names></name> <name><surname>Wakisaka</surname> <given-names>A</given-names></name> <name><surname>Aizawa</surname> <given-names>M</given-names></name></person-group>. <article-title>Close association of HLA-Bw51 with Beh&#x000E7;et&#x02019;s disease</article-title>. <source>Arch Ophthalmol</source> (<year>1982</year>) <volume>100</volume>:<fpage>1455</fpage>&#x02013;<lpage>8</lpage>.<pub-id pub-id-type="doi">10.1001/archopht.1982.01030040433013</pub-id><pub-id pub-id-type="pmid">6956266</pub-id></citation></ref>
<ref id="B9"><label>9</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Mizuki</surname> <given-names>N</given-names></name> <name><surname>Inoko</surname> <given-names>H</given-names></name> <name><surname>Mizuki</surname> <given-names>N</given-names></name> <name><surname>Tanaka</surname> <given-names>H</given-names></name> <name><surname>Kera</surname> <given-names>J</given-names></name> <name><surname>Tsuiji</surname> <given-names>K</given-names></name> <etal/></person-group> <article-title>Human leukocyte antigen serologic and DNA typing of Beh&#x000E7;et&#x02019;s disease and its primary association with <italic>B51</italic></article-title>. <source>Invest Ophthalmol Vis Sci</source> (<year>1992</year>) <volume>33</volume>:<fpage>3332</fpage>&#x02013;<lpage>40</lpage>.<pub-id pub-id-type="pmid">1358857</pub-id></citation></ref>
<ref id="B10"><label>10</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Yazici</surname> <given-names>H</given-names></name> <name><surname>Fresko</surname> <given-names>I</given-names></name> <name><surname>Yurdakul</surname> <given-names>S</given-names></name></person-group>. <article-title>Behcet&#x02019;s syndrome: disease manifestations, management, and advances in treatment</article-title>. <source>Nat Clin Pract Rheumatol</source> (<year>2007</year>) <volume>3</volume>:<fpage>148</fpage>&#x02013;<lpage>55</lpage>.<pub-id pub-id-type="doi">10.1038/ncprheum0436</pub-id><pub-id pub-id-type="pmid">17334337</pub-id></citation></ref>
<ref id="B11"><label>11</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Karasneh</surname> <given-names>J</given-names></name> <name><surname>G&#x000FC;l</surname> <given-names>A</given-names></name> <name><surname>Ollier</surname> <given-names>WE</given-names></name> <name><surname>Silman</surname> <given-names>AJ</given-names></name> <name><surname>Worthington</surname> <given-names>J</given-names></name></person-group>. <article-title>Whole-genome screening for susceptibility genes in multicase families with Beh&#x000E7;et&#x02019;s disease</article-title>. <source>Arthritis Rheum</source> (<year>2005</year>) <volume>52</volume>:<fpage>1836</fpage>&#x02013;<lpage>42</lpage>.<pub-id pub-id-type="doi">10.1002/art.21060</pub-id><pub-id pub-id-type="pmid">15934084</pub-id></citation></ref>
<ref id="B12"><label>12</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Fei</surname> <given-names>Y</given-names></name> <name><surname>Webb</surname> <given-names>R</given-names></name> <name><surname>Cobb</surname> <given-names>BL</given-names></name> <name><surname>Direskeneli</surname> <given-names>H</given-names></name> <name><surname>Saruhan-Direskeneli</surname> <given-names>G</given-names></name> <name><surname>Sawalha</surname> <given-names>AH</given-names></name></person-group>. <article-title>Identification of novel genetic susceptibility loci for Beh&#x000E7;et&#x02019;s disease using a genome-wide association study</article-title>. <source>Arthritis Res Ther</source> (<year>2009</year>) <volume>11</volume>:<fpage>R66</fpage>.<pub-id pub-id-type="doi">10.1186/ar2695</pub-id><pub-id pub-id-type="pmid">19442274</pub-id></citation></ref>
<ref id="B13"><label>13</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Remmers</surname> <given-names>EF</given-names></name> <name><surname>Cosan</surname> <given-names>F</given-names></name> <name><surname>Kirino</surname> <given-names>Y</given-names></name> <name><surname>Ombrello</surname> <given-names>MJ</given-names></name> <name><surname>Abaci</surname> <given-names>N</given-names></name> <name><surname>Satorius</surname> <given-names>C</given-names></name> <etal/></person-group> <article-title>Genome-wide association study identifies variants in the MHC class I, IL10, and IL23R-IL12RB2 regions associated with Beh&#x000E7;et&#x02019;s disease</article-title>. <source>Nat Genet</source> (<year>2010</year>) <volume>42</volume>:<fpage>698</fpage>&#x02013;<lpage>702</lpage>.<pub-id pub-id-type="doi">10.1038/ng.625</pub-id><pub-id pub-id-type="pmid">20622878</pub-id></citation></ref>
<ref id="B14"><label>14</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Mizuki</surname> <given-names>N</given-names></name> <name><surname>Meguro</surname> <given-names>A</given-names></name> <name><surname>Ota</surname> <given-names>M</given-names></name> <name><surname>Ohno</surname> <given-names>S</given-names></name> <name><surname>Shiota</surname> <given-names>T</given-names></name> <name><surname>Kawagoe</surname> <given-names>T</given-names></name> <etal/></person-group> <article-title>Genome-wide association studies identify IL23R-IL12RB2 and IL10 as Beh&#x000E7;et&#x02019;s disease susceptibility loci</article-title>. <source>Nat Genet</source> (<year>2010</year>) <volume>42</volume>:<fpage>703</fpage>&#x02013;<lpage>6</lpage>.<pub-id pub-id-type="doi">10.1038/ng.624</pub-id><pub-id pub-id-type="pmid">20622879</pub-id></citation></ref>
<ref id="B15"><label>15</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Esin</surname> <given-names>S</given-names></name> <name><surname>G&#x000FC;l</surname> <given-names>A</given-names></name> <name><surname>Hodara</surname> <given-names>V</given-names></name> <name><surname>Jeddi-Tehrani</surname> <given-names>M</given-names></name> <name><surname>Dilsen</surname> <given-names>N</given-names></name> <name><surname>Koni&#x000E7;e</surname> <given-names>M</given-names></name> <etal/></person-group> <article-title>Peripheral blood T cell expansions in patients with Behcet&#x02019;s disease</article-title>. <source>Clin Exp Immunol</source> (<year>1997</year>) <volume>107</volume>:<fpage>520</fpage>&#x02013;<lpage>7</lpage>.<pub-id pub-id-type="pmid">9067527</pub-id></citation></ref>
<ref id="B16"><label>16</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Freysdottir</surname> <given-names>J</given-names></name> <name><surname>Lau</surname> <given-names>S</given-names></name> <name><surname>Fortune</surname> <given-names>F</given-names></name></person-group>. <article-title>Gammadelta T cells in Beh&#x000E7;et&#x02019;s disease (BD) and recurrent aphthous stomatitis (RAS)</article-title>. <source>Clin Exp Immunol</source> (<year>1999</year>) <volume>118</volume>:<fpage>451</fpage>&#x02013;<lpage>7</lpage>.<pub-id pub-id-type="pmid">10594567</pub-id></citation></ref>
<ref id="B17"><label>17</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Direskeneli</surname> <given-names>H</given-names></name></person-group>. <article-title>Behcet&#x02019;s disease: infectious aetiolozgy, new autoantigens, and HLA-B51</article-title>. <source>Ann Rheum Dis</source> (<year>2001</year>) <volume>60</volume>:<fpage>996</fpage>&#x02013;<lpage>1002</lpage>.<pub-id pub-id-type="doi">10.1136/ard.60.11.996</pub-id></citation></ref>
<ref id="B18"><label>18</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Kulaber</surname> <given-names>A</given-names></name> <name><surname>Tugal-Tutkun</surname> <given-names>I</given-names></name> <name><surname>Yent&#x000FC;r</surname> <given-names>SP</given-names></name> <name><surname>Akman-Demir</surname> <given-names>G</given-names></name> <name><surname>Kaneko</surname> <given-names>F</given-names></name> <name><surname>G&#x000FC;l</surname> <given-names>A</given-names></name> <etal/></person-group> <article-title>Pro-inflammatory cellular immune response in Beh&#x000E7;et&#x02019;s disease</article-title>. <source>Rheumatol Int</source> (<year>2007</year>) <volume>27</volume>:<fpage>1113</fpage>&#x02013;<lpage>8</lpage>.<pub-id pub-id-type="doi">10.1007/s00296-007-0367-9</pub-id><pub-id pub-id-type="pmid">17549482</pub-id></citation></ref>
<ref id="B19"><label>19</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Raziuddin</surname> <given-names>S</given-names></name> <name><surname>al-Dalaan</surname> <given-names>A</given-names></name> <name><surname>Bahabri</surname> <given-names>S</given-names></name> <name><surname>Siraj</surname> <given-names>AK</given-names></name> <name><surname>al-Sedairy</surname> <given-names>S</given-names></name></person-group>. <article-title>Divergent cytokine production profile in Beh&#x000E7;et&#x02019;s disease. Altered Th1/Th2 cell cytokine pattern</article-title>. <source>J Rheumatol</source> (<year>1998</year>) <volume>25</volume>:<fpage>329</fpage>&#x02013;<lpage>33</lpage>.<pub-id pub-id-type="pmid">9489829</pub-id></citation></ref>
<ref id="B20"><label>20</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Hamzaoui</surname> <given-names>K</given-names></name> <name><surname>Hamzaoui</surname> <given-names>A</given-names></name> <name><surname>Guemira</surname> <given-names>F</given-names></name> <name><surname>Bessioud</surname> <given-names>M</given-names></name> <name><surname>Hamza</surname> <given-names>M</given-names></name> <name><surname>Ayed</surname> <given-names>K</given-names></name></person-group>. <article-title>Cytokine profile in Beh&#x000E7;et&#x02019;s disease patients. Relationship with disease activity</article-title>. <source>Scand J Rheumatol</source> (<year>2002</year>) <volume>31</volume>:<fpage>205</fpage>&#x02013;<lpage>10</lpage>.<pub-id pub-id-type="doi">10.1080/030097402320318387</pub-id><pub-id pub-id-type="pmid">12369651</pub-id></citation></ref>
<ref id="B21"><label>21</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Ben Ahmed</surname> <given-names>M</given-names></name> <name><surname>Houman</surname> <given-names>H</given-names></name> <name><surname>Miled</surname> <given-names>M</given-names></name> <name><surname>Dellagi</surname> <given-names>K</given-names></name> <name><surname>Louzir</surname> <given-names>H</given-names></name></person-group>. <article-title>Involvement of chemokines and Th1 cytokines in the pathogenesis of mucocutaneous lesions of Beh&#x000E7;et&#x02019;s disease</article-title>. <source>Arthritis Rheum</source> (<year>2004</year>) <volume>50</volume>:<fpage>2291</fpage>&#x02013;<lpage>5</lpage>.<pub-id pub-id-type="doi">10.1002/art.20334</pub-id><pub-id pub-id-type="pmid">15248229</pub-id></citation></ref>
<ref id="B22"><label>22</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Lee</surname> <given-names>EB</given-names></name> <name><surname>Kim</surname> <given-names>JY</given-names></name> <name><surname>Lee</surname> <given-names>YJ</given-names></name> <name><surname>Park</surname> <given-names>MH</given-names></name> <name><surname>Song</surname> <given-names>YW</given-names></name></person-group>. <article-title>TNF and TNF receptor polymorphisms in Korean Behcet&#x02019;s disease patients</article-title>. <source>Hum Immunol</source> (<year>2003</year>) <volume>64</volume>:<fpage>614</fpage>&#x02013;<lpage>20</lpage>.<pub-id pub-id-type="doi">10.1016/S0198-8859(03)00057-0</pub-id><pub-id pub-id-type="pmid">12770792</pub-id></citation></ref>
<ref id="B23"><label>23</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Akdeniz</surname> <given-names>N</given-names></name> <name><surname>Esrefoglu</surname> <given-names>M</given-names></name> <name><surname>Keles</surname> <given-names>MS</given-names></name> <name><surname>Karakuzu</surname> <given-names>A</given-names></name> <name><surname>Atasoy</surname> <given-names>M</given-names></name></person-group>. <article-title>Serum interleukin-2, interleukin-6, tumour necrosis factor-alpha and nitric oxide levels in patients with Behcet&#x02019;s disease</article-title>. <source>Ann Acad Med Singapore</source> (<year>2004</year>) <volume>33</volume>:<fpage>596</fpage>&#x02013;<lpage>9</lpage>.<pub-id pub-id-type="pmid">15531955</pub-id></citation></ref>
<ref id="B24"><label>24</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Oztas</surname> <given-names>MO</given-names></name> <name><surname>Onder</surname> <given-names>M</given-names></name> <name><surname>Gurer</surname> <given-names>MA</given-names></name> <name><surname>Bukan</surname> <given-names>N</given-names></name> <name><surname>Sancak</surname> <given-names>B</given-names></name></person-group>. <article-title>Serum interleukin 18 and tumour necrosis factor-alpha levels are increased in Behcet&#x02019;s disease</article-title>. <source>Clin Exp Dermatol</source> (<year>2005</year>) <volume>30</volume>:<fpage>61</fpage>&#x02013;<lpage>3</lpage>.<pub-id pub-id-type="doi">10.1111/j.1365-2230.2004.01684.x</pub-id><pub-id pub-id-type="pmid">15663506</pub-id></citation></ref>
<ref id="B25"><label>25</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Vassalli</surname> <given-names>P</given-names></name></person-group>. <article-title>The pathophysiology of tumor necrosis factors</article-title>. <source>Annu Rev Immunol</source> (<year>1992</year>) <volume>10</volume>:<fpage>411</fpage>&#x02013;<lpage>52</lpage>.<pub-id pub-id-type="doi">10.1146/annurev.iy.10.040192.002211</pub-id></citation></ref>
<ref id="B26"><label>26</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Hofmann</surname> <given-names>SR</given-names></name> <name><surname>R&#x000F6;sen-Wolff</surname> <given-names>A</given-names></name> <name><surname>Tsokos</surname> <given-names>GC</given-names></name> <name><surname>Hedrich</surname> <given-names>CM</given-names></name></person-group>. <article-title>Biological properties and regulation of IL-10 related cytokines and their contribution to autoimmune disease and tissue injury</article-title>. <source>Clin Immunol</source> (<year>2012</year>) <volume>143</volume>:<fpage>116</fpage>&#x02013;<lpage>27</lpage>.<pub-id pub-id-type="doi">10.1016/j.clim.2012.02.005</pub-id><pub-id pub-id-type="pmid">22459704</pub-id></citation></ref>
<ref id="B27"><label>27</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Iyer</surname> <given-names>SS</given-names></name> <name><surname>Cheng</surname> <given-names>G</given-names></name></person-group>. <article-title>Role of interleukin 10 transcriptional regulation in inflammation and autoimmune disease</article-title>. <source>Crit Rev Immunol</source> (<year>2012</year>) <volume>32</volume>:<fpage>23</fpage>&#x02013;<lpage>63</lpage>.<pub-id pub-id-type="doi">10.1615/CritRevImmunol.v32.i1.30</pub-id><pub-id pub-id-type="pmid">22428854</pub-id></citation></ref>
<ref id="B28"><label>28</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Dai</surname> <given-names>H</given-names></name> <name><surname>Ciric</surname> <given-names>B</given-names></name> <name><surname>Zhang</surname> <given-names>GX</given-names></name> <name><surname>Rostami</surname> <given-names>A</given-names></name></person-group>. <article-title>Interleukin-10 plays a crucial role in suppression of experimental autoimmune encephalomyelitis by Bowman-Birk inhibitor</article-title>. <source>J Neuroimmunol</source> (<year>2012</year>) <volume>245</volume>:<fpage>1</fpage>&#x02013;<lpage>7</lpage>.<pub-id pub-id-type="doi">10.1016/j.jneuroim.2012.01.005</pub-id><pub-id pub-id-type="pmid">22365083</pub-id></citation></ref>
<ref id="B29"><label>29</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Makhatadze</surname> <given-names>NJ</given-names></name></person-group>. <article-title>Tumor necrosis factor locus: genetic organisation and biological implications</article-title>. <source>Hum Immunol</source> (<year>1998</year>) <volume>59</volume>:<fpage>571</fpage>&#x02013;<lpage>9</lpage>.<pub-id pub-id-type="doi">10.1016/S0198-8859(98)00056-1</pub-id><pub-id pub-id-type="pmid">9757913</pub-id></citation></ref>
<ref id="B30"><label>30</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Moore</surname> <given-names>KW</given-names></name> <name><surname>de Waal Malefyt</surname> <given-names>R</given-names></name> <name><surname>Coffman</surname> <given-names>RL</given-names></name> <name><surname>O&#x02019;Garra</surname> <given-names>A</given-names></name></person-group>. <article-title>Interleukin-10 and the interleukin-10 receptor</article-title>. <source>Annu Rev Immunol</source> (<year>2001</year>) <volume>19</volume>:<fpage>683</fpage>&#x02013;<lpage>765</lpage>.<pub-id pub-id-type="doi">10.1146/annurev.immunol.19.1.683</pub-id><pub-id pub-id-type="pmid">11244051</pub-id></citation></ref>
<ref id="B31"><label>31</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Lio</surname> <given-names>D</given-names></name> <name><surname>Candore</surname> <given-names>G</given-names></name> <name><surname>Colombo</surname> <given-names>A</given-names></name> <name><surname>Colonna Romano</surname> <given-names>G</given-names></name> <name><surname>Gervasi</surname> <given-names>F</given-names></name> <name><surname>Marino</surname> <given-names>V</given-names></name> <etal/></person-group> <article-title>A genetically determined high setting of TNF alpha influences immunological parameters of HLA-B8, DR3 positive subjects: implications for autoimmunity</article-title>. <source>Hum Immunol</source> (<year>2001</year>) <volume>62</volume>:<fpage>705</fpage>&#x02013;<lpage>13</lpage>.<pub-id pub-id-type="doi">10.1016/S0198-8859(01)00264-6</pub-id><pub-id pub-id-type="pmid">11423177</pub-id></citation></ref>
<ref id="B32"><label>32</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Candore</surname> <given-names>G</given-names></name> <name><surname>Lio</surname> <given-names>D</given-names></name> <name><surname>Colonna Romano</surname> <given-names>G</given-names></name> <name><surname>Caruso</surname> <given-names>C</given-names></name></person-group>. <article-title>Pathogenesis of autoimmune diseases associated with 8.1 ancestral haplotype: effect of multiple gene interactions</article-title>. <source>Autoimmun Rev</source> (<year>2002</year>) <volume>1</volume>:<fpage>29</fpage>&#x02013;<lpage>35</lpage>.<pub-id pub-id-type="doi">10.1016/S1568-9972(01)00004-0</pub-id><pub-id pub-id-type="pmid">12849055</pub-id></citation></ref>
<ref id="B33"><label>33</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Belguendouz</surname> <given-names>H</given-names></name> <name><surname>Messaoud&#x000E8;ne</surname> <given-names>D</given-names></name> <name><surname>Lahmar</surname> <given-names>K</given-names></name> <name><surname>Ahmedi</surname> <given-names>L</given-names></name> <name><surname>Medjeber</surname> <given-names>O</given-names></name> <name><surname>Hartani</surname> <given-names>D</given-names></name> <etal/></person-group> <article-title>Interferon-&#x003B3; and nitric oxide production during Beh&#x000E7;et uveitis: immunomodulatory effect of interleukin-10</article-title>. <source>J Interferon Cytokine Res</source> (<year>2011</year>) <volume>31</volume>:<fpage>643</fpage>&#x02013;<lpage>51</lpage>.<pub-id pub-id-type="doi">10.1089/jir.2010.0148</pub-id><pub-id pub-id-type="pmid">21510811</pub-id></citation></ref>
<ref id="B34"><label>34</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Arayssi</surname> <given-names>T</given-names></name> <name><surname>Hamra</surname> <given-names>R</given-names></name> <name><surname>Homeidan</surname> <given-names>F</given-names></name> <name><surname>Uthman</surname> <given-names>I</given-names></name> <name><surname>Awwad</surname> <given-names>ST</given-names></name> <name><surname>Mroue</surname> <given-names>K</given-names></name> <etal/></person-group> <article-title>The efficacy of a single dose of infliximab in the treatment of Behcet&#x02019;s disease uveitis</article-title>. <source>Clin Exp Rheumatol</source> (<year>2005</year>) <volume>23</volume>:<fpage>427</fpage>.</citation></ref>
<ref id="B35"><label>35</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Sfikakis</surname> <given-names>PP</given-names></name> <name><surname>Markomichelakis</surname> <given-names>N</given-names></name> <name><surname>Alpsoy</surname> <given-names>E</given-names></name> <name><surname>Assaad-Khalil</surname> <given-names>S</given-names></name> <name><surname>Bodaghi</surname> <given-names>B</given-names></name> <name><surname>Gul</surname> <given-names>A</given-names></name> <etal/></person-group> <article-title>Anti-TNF therapy in the management of Behcet&#x02019;s disease review and basis for recommendations</article-title>. <source>Rheumatology (Oxford)</source> (<year>2007</year>) <volume>46</volume>:<fpage>736</fpage>&#x02013;<lpage>41</lpage>.<pub-id pub-id-type="doi">10.1093/rheumatology/kem034</pub-id></citation></ref>
<ref id="B36"><label>36</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Turner</surname> <given-names>DM</given-names></name> <name><surname>Williams</surname> <given-names>DM</given-names></name> <name><surname>Sankaran</surname> <given-names>D</given-names></name> <name><surname>Lazarus</surname> <given-names>M</given-names></name> <name><surname>Sinnott</surname> <given-names>PJ</given-names></name> <name><surname>Hutchinson</surname> <given-names>IV</given-names></name></person-group>. <article-title>An investigation of polymorphism in the interleukin-10 gene promoter</article-title>. <source>Eur J Immunogenet</source> (<year>1997</year>) <volume>24</volume>:<fpage>1</fpage>&#x02013;<lpage>8</lpage>.<pub-id pub-id-type="doi">10.1111/j.1365-2370.1997.tb00001.x</pub-id></citation></ref>
<ref id="B37"><label>37</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Wilson</surname> <given-names>AG</given-names></name> <name><surname>Symons</surname> <given-names>JA</given-names></name> <name><surname>McDowell</surname> <given-names>TL</given-names></name> <name><surname>McDevitt</surname> <given-names>HO</given-names></name> <name><surname>Duff</surname> <given-names>GW</given-names></name></person-group>. <article-title>Effects of a polymorphism in the human tumor necrosis factor a promoter on transcriptional activation</article-title>. <source>Proc Natl Acad Sci U S A</source> (<year>1997</year>) <volume>94</volume>:<fpage>3195</fpage>&#x02013;<lpage>9</lpage>.<pub-id pub-id-type="doi">10.1073/pnas.94.7.3195</pub-id><pub-id pub-id-type="pmid">9096369</pub-id></citation></ref>
<ref id="B38"><label>38</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Wallace</surname> <given-names>GR</given-names></name> <name><surname>Kondeatis</surname> <given-names>E</given-names></name> <name><surname>Vaughan</surname> <given-names>RW</given-names></name> <name><surname>Verity</surname> <given-names>DH</given-names></name> <name><surname>Chen</surname> <given-names>Y</given-names></name> <name><surname>Fortune</surname> <given-names>F</given-names></name> <etal/></person-group> <article-title>IL-10 genotype analysis in patients with Beh&#x000E7;et&#x02019;s disease</article-title>. <source>Hum Immunol</source> (<year>2007</year>) <volume>68</volume>:<fpage>122</fpage>&#x02013;<lpage>7</lpage>.<pub-id pub-id-type="doi">10.1016/j.humimm.2006.11.010</pub-id><pub-id pub-id-type="pmid">17321902</pub-id></citation></ref>
<ref id="B39"><label>39</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Ates</surname> <given-names>O</given-names></name> <name><surname>Dalyan</surname> <given-names>L</given-names></name> <name><surname>Hatemi</surname> <given-names>G</given-names></name> <name><surname>Hamuryudan</surname> <given-names>V</given-names></name> <name><surname>Topal-Sarikaya</surname> <given-names>A</given-names></name></person-group>. <article-title>Analyses of functional IL10 and TNF-&#x003B1; genotypes in Beh&#x000E7;et&#x02019;s syndrome</article-title>. <source>Mol Biol Rep</source> (<year>2010</year>) <volume>37</volume>:<fpage>3637</fpage>&#x02013;<lpage>41</lpage>.<pub-id pub-id-type="doi">10.1007/s11033-010-0015-4</pub-id><pub-id pub-id-type="pmid">20191386</pub-id></citation></ref>
<ref id="B40"><label>40</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Ahmad</surname> <given-names>T</given-names></name> <name><surname>Wallace</surname> <given-names>GR</given-names></name> <name><surname>James</surname> <given-names>T</given-names></name> <name><surname>Neville</surname> <given-names>M</given-names></name> <name><surname>Bunce</surname> <given-names>M</given-names></name> <name><surname>Mulcahy-Hawes</surname> <given-names>K</given-names></name> <etal/></person-group> <article-title>Mapping the HLA association in Beh&#x000E7;et&#x02019;s disease: a role for tumor necrosis factor polymorphisms?</article-title> <source>Arthritis Rheum</source> (<year>2003</year>) <volume>48</volume>:<fpage>807</fpage>&#x02013;<lpage>13</lpage>.<pub-id pub-id-type="doi">10.1002/art.10815</pub-id><pub-id pub-id-type="pmid">12632436</pub-id></citation></ref>
<ref id="B41"><label>41</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Kamoun</surname> <given-names>M</given-names></name> <name><surname>Chelbi</surname> <given-names>H</given-names></name> <name><surname>Houman</surname> <given-names>MH</given-names></name> <name><surname>Lacheb</surname> <given-names>J</given-names></name> <name><surname>Hamzaoui</surname> <given-names>K</given-names></name></person-group>. <article-title>Tumor necrosis factor gene polymorphisms in Tunisian patients with Behcet&#x02019;s disease</article-title>. <source>Hum Immunol</source> (<year>2007</year>) <volume>683</volume>:<fpage>201</fpage>&#x02013;<lpage>5</lpage>.<pub-id pub-id-type="doi">10.1016/j.humimm.2006.12.006</pub-id><pub-id pub-id-type="pmid">17349875</pub-id></citation></ref>
<ref id="B42"><label>42</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Touma</surname> <given-names>Z</given-names></name> <name><surname>Farra</surname> <given-names>C</given-names></name> <name><surname>Hamdan</surname> <given-names>A</given-names></name> <name><surname>Shamseddeen</surname> <given-names>W</given-names></name> <name><surname>Uthman</surname> <given-names>I</given-names></name> <name><surname>Hourani</surname> <given-names>H</given-names></name> <etal/></person-group> <article-title>TNF Polymorphisms in patients with Beh&#x000E7;et&#x02019;s disease: a meta-analysis</article-title>. <source>Arch Med Res</source> (<year>2010</year>) <volume>41</volume>:<fpage>142</fpage>&#x02013;<lpage>6</lpage>.<pub-id pub-id-type="doi">10.1016/j.arcmed.2010.02.002</pub-id></citation></ref>
<ref id="B43"><label>43</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Radouane</surname> <given-names>A</given-names></name> <name><surname>Oudghiri</surname> <given-names>M</given-names></name> <name><surname>Chakib</surname> <given-names>A</given-names></name> <name><surname>Bennani</surname> <given-names>S</given-names></name> <name><surname>Touitou</surname> <given-names>I</given-names></name> <name><surname>Barat-Houari</surname> <given-names>M</given-names></name></person-group>. <article-title>SNPs in the TNF-a gene promoter associated with Beh&#x000E7;et&#x02019;s disease in Moroccan patients</article-title>. <source>Rheumatology (Oxford)</source> (<year>2012</year>) <volume>51</volume>:<fpage>1595</fpage>&#x02013;<lpage>9</lpage>.<pub-id pub-id-type="doi">10.1093/rheumatology/kes141</pub-id><pub-id pub-id-type="pmid">22711844</pub-id></citation></ref>
<ref id="B44"><label>44</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Guenane</surname> <given-names>H</given-names></name> <name><surname>Hartani</surname> <given-names>D</given-names></name> <name><surname>Chachoua</surname> <given-names>L</given-names></name> <name><surname>Lahlou-Boukoffa</surname> <given-names>OS</given-names></name> <name><surname>Mazari</surname> <given-names>F</given-names></name> <name><surname>Touil-Boukoffa</surname> <given-names>C</given-names></name></person-group>. <article-title>Production of Th1/Th2 cytokines and nitric oxide in Beh&#x000E7;et&#x02019;s uveitis and idiopathic uveitis</article-title>. <source>J Fr Ophtalmol</source> (<year>2006</year>) <volume>29</volume>:<fpage>146</fpage>&#x02013;<lpage>52</lpage>. doi:JFO-02-2006-29-2-0181-5512-101019-200508206<pub-id pub-id-type="pmid">16523155</pub-id></citation></ref>
<ref id="B45"><label>45</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Belguendouz</surname> <given-names>H</given-names></name> <name><surname>Messaoudene</surname> <given-names>D</given-names></name> <name><surname>Hartani</surname> <given-names>D</given-names></name> <name><surname>Chachoua</surname> <given-names>L</given-names></name> <name><surname>Ahmedi</surname> <given-names>ML</given-names></name> <name><surname>Lahmar-Belguendouz</surname> <given-names>K</given-names></name> <etal/></person-group> <article-title>Effect of corticotherapy on interleukin-8 and -12 and nitric oxide production during Beh&#x000E7;et and idiopathic uveitis</article-title>. <source>J Fr Ophtalmol</source> (<year>2008</year>) <volume>31</volume>:<fpage>387</fpage>&#x02013;<lpage>95</lpage>.<pub-id pub-id-type="doi">10.1016/S0181-5512(08)71433-5</pub-id><pub-id pub-id-type="pmid">18563038</pub-id></citation></ref>
<ref id="B46"><label>46</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Chi</surname> <given-names>W</given-names></name> <name><surname>Yang</surname> <given-names>P</given-names></name> <name><surname>Zhu</surname> <given-names>X</given-names></name> <name><surname>Wang</surname> <given-names>Y</given-names></name> <name><surname>Chen</surname> <given-names>L</given-names></name> <name><surname>Huang</surname> <given-names>X</given-names></name> <etal/></person-group> <article-title>Production of interleukin-17 in Behcet&#x02019;s disease is inhibited by cyclosporin A</article-title>. <source>Mol Vis</source> (<year>2010</year>) <volume>19</volume>:<fpage>880</fpage>&#x02013;<lpage>6</lpage>.<pub-id pub-id-type="pmid">20508866</pub-id></citation></ref>
<ref id="B47"><label>47</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Langrish</surname> <given-names>CL</given-names></name> <name><surname>Chen</surname> <given-names>Y</given-names></name> <name><surname>Blumenschein</surname> <given-names>WM</given-names></name> <name><surname>Mattson</surname> <given-names>J</given-names></name> <name><surname>Basham</surname> <given-names>B</given-names></name> <name><surname>Sedgwick</surname> <given-names>JD</given-names></name> <etal/></person-group> <article-title>IL-23 drives a pathogenic T cell population that induces autoimmune inflammation</article-title>. <source>J Exp Med</source> (<year>2005</year>) <volume>201</volume>:<fpage>233</fpage>&#x02013;<lpage>40</lpage>.<pub-id pub-id-type="doi">10.1084/jem.20041257</pub-id><pub-id pub-id-type="pmid">15657292</pub-id></citation></ref>
<ref id="B48"><label>48</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Collison</surname> <given-names>LW</given-names></name> <name><surname>Vignali</surname> <given-names>DA</given-names></name></person-group>. <article-title>Interleukin-35: odd one out or part of the family?</article-title> <source>Immunol Rev</source> (<year>2008</year>) <volume>226</volume>:<fpage>248</fpage>&#x02013;<lpage>62</lpage>.<pub-id pub-id-type="doi">10.1111/j.1600-065X.2008.00704.x</pub-id><pub-id pub-id-type="pmid">19161429</pub-id></citation></ref>
<ref id="B49"><label>49</label><citation citation-type="journal"><collab>International Study Group for Beh&#x000E7;et&#x02019;s Disease</collab>. <article-title>Criteria for diagnosis of Beh&#x000E7;et&#x02019;s disease. International Study Group for Beh&#x000E7;et&#x02019;s Disease</article-title>. <source>Lancet</source> (<year>1990</year>) <volume>335</volume>:<fpage>1078</fpage>&#x02013;<lpage>80</lpage>.</citation></ref>
<ref id="B50"><label>50</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Glasel</surname> <given-names>JA</given-names></name></person-group>. <article-title>Validity of nucleic acid purities monitored by 260nm/280nm absorbance ratios</article-title>. <source>Biotechniques</source> (<year>1995</year>) <volume>18</volume>:<fpage>62</fpage>&#x02013;<lpage>3</lpage>.</citation></ref>
<ref id="B51"><label>51</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Ding</surname> <given-names>Q</given-names></name> <name><surname>Fan</surname> <given-names>B</given-names></name> <name><surname>Fan</surname> <given-names>Z</given-names></name> <name><surname>Ding</surname> <given-names>L</given-names></name> <name><surname>Li</surname> <given-names>F</given-names></name> <name><surname>Tu</surname> <given-names>W</given-names></name> <etal/></person-group> <article-title>Interleukin-10-819C &#x0003E;T polymorphism contributed to cancer risk: evidence from 29 studies</article-title>. <source>Cytokine</source> (<year>2012</year>) <volume>61</volume>:<fpage>139</fpage>&#x02013;<lpage>45</lpage>.<pub-id pub-id-type="doi">10.1016/j.cyto.2012.09.008</pub-id><pub-id pub-id-type="pmid">23046616</pub-id></citation></ref>
<ref id="B52"><label>52</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Xue</surname> <given-names>H</given-names></name> <name><surname>Wang</surname> <given-names>YC</given-names></name> <name><surname>Lin</surname> <given-names>B</given-names></name> <name><surname>An</surname> <given-names>J</given-names></name> <name><surname>Chen</surname> <given-names>L</given-names></name> <name><surname>Chen</surname> <given-names>J</given-names></name> <etal/></person-group> <article-title>A meta-analysis of interleukin-10 -592 promoter polymorphism associated with gastric cancer risk</article-title>. <source>PLoS One</source> (<year>2012</year>) <volume>7</volume>:<fpage>e39868</fpage>.<pub-id pub-id-type="doi">10.1371/journal.pone.0039868</pub-id><pub-id pub-id-type="pmid">22859944</pub-id></citation></ref>
<ref id="B53"><label>53</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Li</surname> <given-names>D</given-names></name> <name><surname>He</surname> <given-names>Q</given-names></name> <name><surname>Li</surname> <given-names>R</given-names></name> <name><surname>Xu</surname> <given-names>X</given-names></name> <name><surname>Chen</surname> <given-names>B</given-names></name> <name><surname>Xie</surname> <given-names>A</given-names></name></person-group>. <article-title>Interleukin-10 promoter polymorphisms in Chinese patients with Parkinson&#x02019;s disease</article-title>. <source>Neurosci Lett</source> (<year>2012</year>) <volume>513</volume>:<fpage>183</fpage>&#x02013;<lpage>6</lpage>.<pub-id pub-id-type="doi">10.1016/j.neulet.2012.02.033</pub-id><pub-id pub-id-type="pmid">22387064</pub-id></citation></ref>
<ref id="B54"><label>54</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Zhong</surname> <given-names>Q</given-names></name> <name><surname>Ding</surname> <given-names>C</given-names></name> <name><surname>Wang</surname> <given-names>M</given-names></name> <name><surname>Sun</surname> <given-names>Y</given-names></name> <name><surname>Xu</surname> <given-names>Y</given-names></name></person-group>. <article-title>Interleukin-10 gene polymorphisms and chronic/aggressive periodontitis susceptibility: a meta-analysis based on 14 case-control studies</article-title>. <source>Cytokine</source> (<year>2012</year>) <volume>60</volume>:<fpage>47</fpage>&#x02013;<lpage>54</lpage>.<pub-id pub-id-type="doi">10.1016/j.cyto.2012.05.014</pub-id><pub-id pub-id-type="pmid">22698805</pub-id></citation></ref>
<ref id="B55"><label>55</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Liang</surname> <given-names>X</given-names></name> <name><surname>Zhang</surname> <given-names>J</given-names></name> <name><surname>Zhu</surname> <given-names>Y</given-names></name> <name><surname>Lu</surname> <given-names>Y</given-names></name> <name><surname>Zhou</surname> <given-names>X</given-names></name> <name><surname>Wang</surname> <given-names>Z</given-names></name> <etal/></person-group> <article-title>Specific genetic polymorphisms of IL10-592AA and IL10-819 TT genotypes lead to the key role for inducing docetaxel-induced liver injury in breast cancer patients</article-title>. <source>Clin Transl Oncol</source> (<year>2013</year>) <volume>15</volume>:<fpage>331</fpage>&#x02013;<lpage>4</lpage>.<pub-id pub-id-type="doi">10.1007/s12094-012-0936-6</pub-id><pub-id pub-id-type="pmid">23143946</pub-id></citation></ref>
<ref id="B56"><label>56</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Temple</surname> <given-names>SE</given-names></name> <name><surname>Lim</surname> <given-names>E</given-names></name> <name><surname>Cheong</surname> <given-names>KY</given-names></name> <name><surname>Almeida</surname> <given-names>CA</given-names></name> <name><surname>Price</surname> <given-names>P</given-names></name> <name><surname>Ardlie</surname> <given-names>KG</given-names></name> <etal/></person-group> <article-title>Alleles carried at positions -819 and -592 of the IL10 promoter affect transcription following stimulation of peripheral blood cells with <italic>Streptococcus pneumoniae</italic></article-title>. <source>Immunogenetics</source> (<year>2003</year>) <volume>55</volume>:<fpage>629</fpage>&#x02013;<lpage>32</lpage>.<pub-id pub-id-type="doi">10.1007/s00251-003-0621-6</pub-id><pub-id pub-id-type="pmid">14605776</pub-id></citation></ref>
<ref id="B57"><label>57</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Lin</surname> <given-names>WP</given-names></name> <name><surname>Lin</surname> <given-names>JH</given-names></name> <name><surname>Chen</surname> <given-names>XW</given-names></name> <name><surname>Wu</surname> <given-names>CY</given-names></name> <name><surname>Zhang</surname> <given-names>LQ</given-names></name> <name><surname>Huang</surname> <given-names>ZD</given-names></name> <etal/></person-group> <article-title>Interleukin-10 promoter polymorphisms associated with susceptibility to lumbar disc degeneration in a Chinese cohort</article-title>. <source>Genet Mol Res</source> (<year>2011</year>) <volume>10</volume>:<fpage>1719</fpage>&#x02013;<lpage>27</lpage>.<pub-id pub-id-type="doi">10.4238/vol10-3gmr1283</pub-id><pub-id pub-id-type="pmid">21863566</pub-id></citation></ref>
<ref id="B58"><label>58</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Tesse</surname> <given-names>R</given-names></name> <name><surname>Del Vecchio</surname> <given-names>GC</given-names></name> <name><surname>De Mattia</surname> <given-names>D</given-names></name> <name><surname>Sangerardi</surname> <given-names>M</given-names></name> <name><surname>Valente</surname> <given-names>F</given-names></name> <name><surname>Giordano</surname> <given-names>P</given-names></name></person-group>. <article-title>Association of interleukin-(IL)10 haplotypes and serum IL-10 levels in the progression of childhood immune thrombocytopenic purpura</article-title>. <source>Gene</source> (<year>2012</year>) <volume>505</volume>:<fpage>53</fpage>&#x02013;<lpage>6</lpage>.<pub-id pub-id-type="doi">10.1016/j.gene.2012.05.050</pub-id><pub-id pub-id-type="pmid">22677268</pub-id></citation></ref>
<ref id="B59"><label>59</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Xavier</surname> <given-names>JM</given-names></name> <name><surname>Shahram</surname> <given-names>F</given-names></name> <name><surname>Davatchi</surname> <given-names>F</given-names></name> <name><surname>Rosa</surname> <given-names>A</given-names></name> <name><surname>Crespo</surname> <given-names>J</given-names></name> <name><surname>Abdollahi</surname> <given-names>BS</given-names></name> <etal/></person-group> <article-title>Association study of IL10 and IL23R-IL12RB2 in Iranian patients with Beh&#x000E7;et&#x02019;s disease</article-title>. <source>Arthritis Rheum</source> (<year>2012</year>) <volume>64</volume>:<fpage>2761</fpage>&#x02013;<lpage>72</lpage>.<pub-id pub-id-type="doi">10.1002/art.34437</pub-id><pub-id pub-id-type="pmid">22378604</pub-id></citation></ref>
<ref id="B60"><label>60</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Jang</surname> <given-names>WC</given-names></name> <name><surname>Nam</surname> <given-names>YH</given-names></name> <name><surname>Ahn</surname> <given-names>YC</given-names></name> <name><surname>Lee</surname> <given-names>SH</given-names></name> <name><surname>Park</surname> <given-names>SH</given-names></name> <name><surname>Choe</surname> <given-names>JY</given-names></name> <etal/></person-group> <article-title>Interleukin-17F gene polymorphisms in Korean patients with Behcet&#x02019;s disease</article-title>. <source>Rheumato Int</source> (<year>2008</year>) <volume>29</volume>:<fpage>173</fpage>&#x02013;<lpage>8</lpage>.<pub-id pub-id-type="doi">10.1007/s00296-008-0664-y</pub-id><pub-id pub-id-type="pmid">18769923</pub-id></citation></ref>
<ref id="B61"><label>61</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Jiang</surname> <given-names>Z</given-names></name> <name><surname>Yang</surname> <given-names>P</given-names></name> <name><surname>Hou</surname> <given-names>S</given-names></name> <name><surname>Du</surname> <given-names>L</given-names></name> <name><surname>Xie</surname> <given-names>L</given-names></name> <name><surname>Zhou</surname> <given-names>H</given-names></name> <etal/></person-group> <article-title>IL-23R gene confers susceptibility to Behcet&#x02019;s disease in a Chinese Han population</article-title>. <source>Ann Rheum Dis</source> (<year>2010</year>) <volume>69</volume>:<fpage>1325</fpage>&#x02013;<lpage>8</lpage>.<pub-id pub-id-type="doi">10.1136/ard.2009.119420</pub-id><pub-id pub-id-type="pmid">20375120</pub-id></citation></ref>
<ref id="B62"><label>62</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Kim</surname> <given-names>ES</given-names></name> <name><surname>Kim</surname> <given-names>SW</given-names></name> <name><surname>Moon</surname> <given-names>CM</given-names></name> <name><surname>Park</surname> <given-names>JJ</given-names></name> <name><surname>Kim</surname> <given-names>TI</given-names></name> <name><surname>Kim</surname> <given-names>WH</given-names></name> <etal/></person-group> <article-title>Interactions between IL17A, IL23R, and STAT4 polymorphisms confer susceptibility to intestinal Behcet&#x02019;s disease in Korean population</article-title>. <source>Life Sci</source> (<year>2012</year>) <volume>90</volume>:<fpage>740</fpage>&#x02013;<lpage>6</lpage>.<pub-id pub-id-type="doi">10.1016/j.lfs.2012.03.017</pub-id><pub-id pub-id-type="pmid">22483685</pub-id></citation></ref>
<ref id="B63"><label>63</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Kastelein</surname> <given-names>RA</given-names></name> <name><surname>Hunter</surname> <given-names>CA</given-names></name> <name><surname>Cua</surname> <given-names>DJ</given-names></name></person-group>. <article-title>Discovery and biology of IL-23 and IL-27: related but functionally distinct regulators of inflammation</article-title>. <source>Annu Rev Immunol</source> (<year>2007</year>) <volume>25</volume>:<fpage>221</fpage>&#x02013;<lpage>42</lpage>.<pub-id pub-id-type="doi">10.1146/annurev.immunol.22.012703.104758</pub-id><pub-id pub-id-type="pmid">17291186</pub-id></citation></ref>
<ref id="B64"><label>64</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Paunovic</surname> <given-names>V</given-names></name> <name><surname>Carroll</surname> <given-names>HP</given-names></name> <name><surname>Vandenbroeck</surname> <given-names>K</given-names></name> <name><surname>Gadina</surname> <given-names>M</given-names></name></person-group>. <article-title>Signalling, inflammation and arthritis: crossed signals: the role of interleukin (IL)-12, -17, -23 and -27 in autoimmunity</article-title>. <source>Rheumatology</source> (<year>2008</year>) <volume>47</volume>:<fpage>771</fpage>&#x02013;<lpage>6</lpage>.<pub-id pub-id-type="doi">10.1093/rheumatology/kem352</pub-id><pub-id pub-id-type="pmid">18238793</pub-id></citation></ref>
<ref id="B65"><label>65</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Hirschfield</surname> <given-names>GM</given-names></name> <name><surname>Liu</surname> <given-names>X</given-names></name> <name><surname>Xu</surname> <given-names>C</given-names></name> <name><surname>Lu</surname> <given-names>Y</given-names></name> <name><surname>Xie</surname> <given-names>G</given-names></name> <name><surname>Lu</surname> <given-names>Y</given-names></name> <etal/></person-group> <article-title>Primary biliary cirrosis associated with HLA, IL12A and IL12RB2 variants</article-title>. <source>N Engl J Med</source> (<year>2009</year>) <volume>360</volume>:<fpage>2544</fpage>&#x02013;<lpage>55</lpage>.<pub-id pub-id-type="doi">10.1056/NEJMoa0810440</pub-id><pub-id pub-id-type="pmid">19458352</pub-id></citation></ref>
<ref id="B66"><label>66</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Liu</surname> <given-names>X</given-names></name> <name><surname>Invernizzi</surname> <given-names>P</given-names></name> <name><surname>Lu</surname> <given-names>Y</given-names></name> <name><surname>Kosoy</surname> <given-names>R</given-names></name> <name><surname>Lu</surname> <given-names>Y</given-names></name> <name><surname>Bianchi</surname> <given-names>I</given-names></name> <etal/></person-group> <article-title>Genome-wide meta-analyses identify three loci associated with primary biliary cirrosis</article-title>. <source>Nat Genet</source> (<year>2010</year>) <volume>42</volume>:<fpage>658</fpage>&#x02013;<lpage>60</lpage>.<pub-id pub-id-type="doi">10.1038/ng.627</pub-id><pub-id pub-id-type="pmid">20639880</pub-id></citation></ref>
<ref id="B67"><label>67</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Mells</surname> <given-names>GF</given-names></name> <name><surname>Floyd</surname> <given-names>JA</given-names></name> <name><surname>Morley</surname> <given-names>KI</given-names></name> <name><surname>Cordell</surname> <given-names>HJ</given-names></name> <name><surname>Franklin</surname> <given-names>CS</given-names></name> <name><surname>Shin</surname> <given-names>SY</given-names></name> <etal/></person-group> <article-title>Genome-wide association study identifies 12 new susceptibility loci for primary biliary cirrhosis</article-title>. <source>Nat Genet</source> (<year>2011</year>) <volume>43</volume>:<fpage>329</fpage>&#x02013;<lpage>32</lpage>.<pub-id pub-id-type="doi">10.1038/ng.789</pub-id><pub-id pub-id-type="pmid">21399635</pub-id></citation></ref>
<ref id="B68"><label>68</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Park</surname> <given-names>K</given-names></name> <name><surname>Kim</surname> <given-names>N</given-names></name> <name><surname>Nam</surname> <given-names>J</given-names></name> <name><surname>Bang</surname> <given-names>D</given-names></name> <name><surname>Lee</surname> <given-names>ES</given-names></name></person-group>. <article-title>Association of TNFA promoter region haplotype in Beh&#x000E7;et&#x02019;s disease</article-title>. <source>J Korean Med Sci</source> (<year>2006</year>) <volume>21</volume>:<fpage>596</fpage>&#x02013;<lpage>601</lpage>.<pub-id pub-id-type="doi">10.3346/jkms.2006.21.4.596</pub-id><pub-id pub-id-type="pmid">16891799</pub-id></citation></ref>
<ref id="B69"><label>69</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Akman</surname> <given-names>A</given-names></name> <name><surname>Sallakci</surname> <given-names>N</given-names></name> <name><surname>Kacaroglu</surname> <given-names>H</given-names></name> <name><surname>Tosun</surname> <given-names>O</given-names></name> <name><surname>Yavuzer</surname> <given-names>U</given-names></name> <name><surname>Alpsoy</surname> <given-names>E</given-names></name> <etal/></person-group> <article-title>Relationship between periodontal findings and the TNF-alpha gene 1031T/C polymorphism in Turkish patients with Behcet&#x02019;s disease</article-title>. <source>J Eur Acad Dermatol Venereol</source> (<year>2008</year>) <volume>22</volume>:<fpage>950</fpage>&#x02013;<lpage>7</lpage>.<pub-id pub-id-type="doi">10.1111/j.1468-3083.2008.02678.x</pub-id><pub-id pub-id-type="pmid">18355201</pub-id></citation></ref>
<ref id="B70"><label>70</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Orchard</surname> <given-names>TR</given-names></name> <name><surname>Chua</surname> <given-names>CN</given-names></name> <name><surname>Ahmad</surname> <given-names>T</given-names></name> <name><surname>Cheng</surname> <given-names>H</given-names></name> <name><surname>Welsh</surname> <given-names>KI</given-names></name> <name><surname>Jewell</surname> <given-names>DP</given-names></name></person-group>. <article-title>Uveitis and erythema nodosum in inflammatory bowel isease: clinical features and the role of HLA genes</article-title>. <source>Gastroenterology</source> (<year>2002</year>) <volume>123</volume>:<fpage>714</fpage>&#x02013;<lpage>8</lpage>.<pub-id pub-id-type="doi">10.1053/gast.2002.35396</pub-id><pub-id pub-id-type="pmid">12198697</pub-id></citation></ref>
<ref id="B71"><label>71</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Higuchi</surname> <given-names>T</given-names></name> <name><surname>Seki</surname> <given-names>N</given-names></name> <name><surname>Kamizono</surname> <given-names>S</given-names></name> <name><surname>Yamada</surname> <given-names>A</given-names></name> <name><surname>Kimura</surname> <given-names>A</given-names></name> <name><surname>Kato</surname> <given-names>H</given-names></name> <etal/></person-group> <article-title>Polymorphism of the 5&#x02019; flanking region of the human tumor necrosis factor (TNF)-alpha gene in Japanese</article-title>. <source>Tissue Antigens</source> (<year>1998</year>) <volume>51</volume>:<fpage>605</fpage>&#x02013;<lpage>12</lpage>.<pub-id pub-id-type="doi">10.1111/j.1399-0039.1998.tb03002.x</pub-id><pub-id pub-id-type="pmid">9694352</pub-id></citation></ref>
<ref id="B72"><label>72</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Brinkman</surname> <given-names>BM</given-names></name> <name><surname>Zuijdeest</surname> <given-names>D</given-names></name> <name><surname>Kaijzel</surname> <given-names>EL</given-names></name> <name><surname>Breedveld</surname> <given-names>FC</given-names></name> <name><surname>Verweij</surname> <given-names>CL</given-names></name></person-group>. <article-title>Relevance of the tumor necrosis factor alpha (TNF alpha) -308 promoter polymorphism in TNF alpha gene regulation</article-title>. <source>J Inflamm</source> (<year>1995</year>) <volume>46</volume>:<fpage>32</fpage>&#x02013;<lpage>41</lpage>.<pub-id pub-id-type="pmid">8832970</pub-id></citation></ref>
<ref id="B73"><label>73</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Uglialoro</surname> <given-names>AM</given-names></name> <name><surname>Turbay</surname> <given-names>D</given-names></name> <name><surname>Pesavento</surname> <given-names>PA</given-names></name> <name><surname>Delgado</surname> <given-names>JC</given-names></name> <name><surname>McKenzie</surname> <given-names>FE</given-names></name> <name><surname>Gribben</surname> <given-names>JG</given-names></name> <etal/></person-group> <article-title>Identification of three new single nucleotide polymorphisms in the human tumor necrosis factor-alpha gene promoter</article-title>. <source>Tissue Antigens</source> (<year>1998</year>) <volume>52</volume>:<fpage>359</fpage>&#x02013;<lpage>67</lpage>.<pub-id pub-id-type="doi">10.1111/j.1399-0039.1998.tb03056.x</pub-id><pub-id pub-id-type="pmid">9820599</pub-id></citation></ref>
<ref id="B74"><label>74</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Skoog</surname> <given-names>T</given-names></name> <name><surname>van&#x02019;t Hooft</surname> <given-names>FM</given-names></name> <name><surname>Kallin</surname> <given-names>B</given-names></name> <name><surname>Jovinge</surname> <given-names>S</given-names></name> <name><surname>Boquist</surname> <given-names>S</given-names></name> <name><surname>Nilsson</surname> <given-names>J</given-names></name> <etal/></person-group> <article-title>A common functional polymorphism (C &#x02013; &#x0003E;A substitution at position -863) in the promoter region of the tumour necrosis factor-alpha (TNF-alpha) gene associated with reduced circulating levels of TNF-alpha</article-title>. <source>Hum Mol Genet</source> (<year>1999</year>) <volume>8</volume>:<fpage>1443</fpage>&#x02013;<lpage>9</lpage>.<pub-id pub-id-type="doi">10.1093/hmg/8.8.1443</pub-id><pub-id pub-id-type="pmid">10400991</pub-id></citation></ref>
<ref id="B75"><label>75</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Kaijzel</surname> <given-names>EL</given-names></name> <name><surname>Bayley</surname> <given-names>JP</given-names></name> <name><surname>van Krugten</surname> <given-names>MV</given-names></name> <name><surname>Smith</surname> <given-names>L</given-names></name> <name><surname>van de Linde</surname> <given-names>P</given-names></name> <name><surname>Bakker</surname> <given-names>AM</given-names></name> <etal/></person-group> <article-title>Allele-specific quantification of tumor necrosis factor alpha (TNF) transcription and the role of promoter polymorphisms in rheumatoid arthritis patients and healthy individuals</article-title>. <source>Genes Immun</source> (<year>2001</year>) <volume>2</volume>:<fpage>135</fpage>&#x02013;<lpage>44</lpage>.<pub-id pub-id-type="doi">10.1038/sj.gene.6363747</pub-id><pub-id pub-id-type="pmid">11426322</pub-id></citation></ref>
<ref id="B76"><label>76</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Jeffreys</surname> <given-names>AJ</given-names></name> <name><surname>Kauppi</surname> <given-names>L</given-names></name> <name><surname>Neumann</surname> <given-names>R</given-names></name></person-group>. <article-title>Intensely punctate meiotic recombination in the class II region of the major histocompatibility complex</article-title>. <source>Nat Genet</source> (<year>2001</year>) <volume>29</volume>:<fpage>217</fpage>&#x02013;<lpage>22</lpage>.<pub-id pub-id-type="doi">10.1038/ng1001-217</pub-id><pub-id pub-id-type="pmid">11586303</pub-id></citation></ref>
</ref-list>
</back>
</article>